

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12P 21/06, C12N 5/00, 15/00 C07H 15/12, 17/00, C07K 3/00 A61K 35/14, 37/24, 37/36	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/17602</b> <b>(43) International Publication Date:</b> 15 October 1992 (15.10.92)
<b>(21) International Application Number:</b> PCT/US92/02821 <b>(22) International Filing Date:</b> 6 April 1992 (06.04.92)  <b>(30) Priority data:</b> 681,702 5 April 1991 (05.04.91) US 864,475 6 April 1992 (06.04.92) US  <b>(71) Applicant:</b> THE GENERAL HOSPITAL CORPORATION OFFICE OF TECHNOLOGY AFFAIRS [US/US]; Thirteenth Street, Building 149, Suite 1101, Charlestown, MA 02129 (US).  <b>(72) Inventors:</b> SEGRE, Gino, V. ; 58 Sedgemoor Road, Wayland, MA 01778 (US). KRONENBERG, Henry, M. ; 48 Hastings Road, Belmont, MA 02178 (US). ABOUSAMRA, Abdul-Badi ; Four Colonial Way, Plainville, MA 02762 (US). JUPPNER, Harald ; Eight Harris Street, Boston, MA 02109 (US). POTTS, John, T., Jr. ; 129 Chestnut Street, West Newton, MA 02165 (US). SCHIPANI, Ernestina ; Four Longfellow Place, Apt. 1004, Boston, MA 02114 (US).	<b>(74) Agent:</b> CLARK, Paul, T.; Fish and Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> PARATHYROID HORMONE RECEPTOR AND DNA ENCODING SAME  <b>(57) Abstract</b>  DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCI on the front pages of pamphlets publishing international applications under the PCI.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

- 1 -

**PARATHYROID HORMONE RECEPTOR AND DNA ENCODING SAME**Background of the Invention

Partial funding of the work described herein was  
5 provided by the U.S. Government, which has certain rights  
to the invention.

The invention relates to endocrine receptors.

A crucial step in the expression of hormonal  
action is the interaction of hormones with receptors on  
10 the plasma membrane surface of target cells. The  
formation of hormone-receptor complexes allows the  
transduction of extracellular signals into the cell to  
elicit a variety of biological responses. For example,  
binding of a hormone such as follicle stimulating hormone  
15 (FSH), luteinizing hormone (LH), thyroid stimulating  
hormone (TSH), and chorionic gonadotropin (CG), to its  
cell surface receptor induces a conformational change in  
the receptor, resulting in the association of the  
receptor with a transductor molecule, the stimulatory  
20 guanine nucleotide (GTP) binding protein, a component of  
which is ( $G_s$ ). This association stimulates adenylate  
cyclase activity which in turn triggers other cellular  
processes such as protein phosphorylation, steroid  
synthesis and secretion, and the modulation of ion flux.  
25 Binding of other hormones, including arginine vasopressin  
(VP), angiotensin II, and norepinephrine, to their cell  
surface receptors results in the activation of other  
types of GTP binding proteins components such as ( $G_p$ ),  
which in turn stimulates the activity of the enzyme  
30 phospholipase C. The products of phospholipase C  
hydrolysis initiate a complex cascade of cellular events,  
including the mobilization of intracellular calcium and  
protein phosphorylation.

Parathyroid hormone (PTH) is a major regulator of  
35 calcium homeostasis whose principal target cells occur in

- 2 -

bone and kidney. Regulation of calcium concentration is necessary for the normal function of the gastrointestinal, skeletal, neurologic, neuromuscular, and cardiovascular systems. PTH synthesis and release

5 are controlled principally by the serum calcium level: a low level stimulates and a high level suppresses both the hormone synthesis and release. PTH, in turn, maintains the serum calcium level by directly or indirectly promoting calcium entry into the blood at three sites of

10 calcium exchange: gut, bone and kidney. PTH contributes to net gastrointestinal absorption of calcium by favoring the renal synthesis of the active form of vitamin D. PTH promotes calcium resorption from bone by inhibiting osteoblasts and, indirectly, by stimulating

15 differentiation of the bone-resorbing cells, osteoclasts. It also mediates at least three main effects on the kidney: stimulation of tubular calcium reabsorption, enhancement of phosphate clearance, and promotion of an increase in the enzyme that completes synthesis of the

20 active form of vitamin D. PTH exerts these effects primarily through receptor-mediated activation of adenylate cyclase, although receptor-mediated activation of phospholipase C by PTH has also been reported (Hruska et al., J. Clin. Invest. 79:230, 1987).

25 Disruption of calcium homeostasis may produce many clinical disorders (e.g., severe bone disease, anemia, renal impairment, ulcers, myopathy, and neuropathy) and usually results from conditions which produce an alteration in the level of parathyroid hormone.

30 Hypercalcemia is a condition which is characterized by an elevation in the serum calcium level. It is often associated with primary hyperparathyroidism in which an excess of PTH production occurs as a result of a lesion (e.g., adenoma, hyperplasia or carcinoma) of the

35 parathyroid glands. Another type of hypercalcemia,

- 3 -

humoral hypercalcemia of malignancy (HHM), is the most common paraneoplastic syndrome. It appears to result in most instances from the production by tumors (e.g., squamous, renal, ovarian or bladder carcinomas) of a novel class of protein hormone which shares amino acid homology with PTH. These PTH-related proteins (PTHrP) appear to mimic certain of the renal and skeletal actions of PTH and are believed to interact with the PTH receptor in these tissues. PTHrP is normally found at low levels in many tissues, including keratinocytes, brain, pituitary, parathyroid, adrenal cortex, medulla, fetal liver, osteoblast-like cells and lactating mammary tissues. In many HHM malignancies, PTHrP is found in the circulatory system at high levels, thereby producing the elevated calcium levels associated with HHM.

#### Summary of the Invention

The invention features isolated DNA comprising a DNA sequence encoding a cell receptor, preferably a parathyroid hormone receptor, of a vertebrate animal, which receptor has an amino acid sequence with at least 30% (preferably at least 50%, even more preferably at least 60%, and most preferably at least 75%) identity to the amino acid sequence shown in FIG. 3 (SEQ ID NO.: 3): i.e., when the closest match is made between the two amino acid sequences (using standard methods), at least 30% of the amino acid residues of the former sequence are identical to the amino acid residues of the latter sequence. By "isolated" is meant that the DNA is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) from which the DNA of the invention is derived, immediately flank the gene encoding the DNA of the invention. The isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or

- 4 -

synthetic DNA. It may be identical to a naturally-occurring, cell receptor- (e.g. PTH receptor) encoding DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more

5 nucleotides. Single-stranded DNAs of the invention are generally at least 8 nucleotides long, (preferably at least 18 nucleotides long, and more preferably at least 30 nucleotides long) ranging up to full length of the gene or cDNA; they preferably are detectably labelled for

10 use as hybridization probes, and may be antisense. Preferably, the isolated DNA hybridizes under conditions of high stringency to all or part of the DNA sequence show in FIG. 1 (SEQ ID NO.:1), FIG. 2 (SEQ ID NO.:2), FIG. 3 (SEQ ID NO.:3), or FIG. 6 (SEQ ID NO.:4). By

15 "high stringency" is meant, for example, conditions such as those described herein below for the isolation of human kidney PTH receptor cDNA (also see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, hereby incorporated by reference). Most

20 preferably, the animal is a mammal (such as an opossum, a rat, or a human), and the DNA sequence encodes substantially all of the amino acid sequence shown in FIG. 1 (SEQ ID NO.:1), FIG. 2 (SEQ ID NO.:2), FIG. 3 (SEQ ID NO.:3) or FIG. 6 (SEQ ID NO.:4); or is encoded by the

25 coding sequence of one of the plasmids deposited with the American Type Culture Collection (ATCC) and designated ATCC Accession No. 68570 or 68571. The DNA of the invention may be incorporated into a vector [which may be provided as a purified preparation (e.g., a vector

30 separated from the mixture of vectors which make up a library)] containing a DNA sequence encoding a cell receptor of the invention (e.g. parathyroid hormone receptor) or fragment of the receptor, and a cell or essentially homogenous population of cells (e.g.,

35 prokaryotic cells, or eukaryotic cells such as mammalian

- 5 -

cells) which contain the vector (or the isolated DNA described above). By "essentially homogenous" is meant that at least 99% of the cells contain the vector of the invention (or the isolated DNA, as the case may be).

- 5 Preferably, this vector (e.g., R15B) is capable of directing expression of a parathyroid hormone receptor (for example, in a cell transfected or transformed with the vector).

In another aspect, the invention features a cell  
10 receptor, preferably parathyroid hormone receptor, (or an essentially purified preparation thereof) produced by expression of a recombinant DNA molecule encoding the cell receptor. An "essentially purified preparation" is one which is substantially free of the proteins and  
15 lipids with which it is naturally associated.

In a related aspect, the invention features a polypeptide which includes a fragment of a naturally-occurring cell receptor of the invention. Preferably, the polypeptide includes a fragment of a naturally-  
20 occurring parathyroid hormone receptor which is capable of binding parathyroid hormone or parathyroid hormone-related protein. In preferred embodiments, this fragment is at least six amino acids long, and has a sequence selected from the group including:

- 25 (a) TNETREREVFDRLGMIYTVG; (SEQ ID NO.: 5)  
(b) YLYSGFTLDEAERLTEEEL; (SEQ ID NO.: 6)  
(c) VTFFLYFLATNYYWILVEG; (SEQ ID NO.: 7)  
(d) Y-RATLANTGCWDLSSGHKKWIIQVP; (SEQ. ID NO.: 8)  
(e) PYTEYSGTLWQIQMHYEM; (SEQ ID NO.: 9)  
30 (f) DDVFTKEEQIFLLHRAQA; (SEQ ID NO.: 10)  
(g) FFRLHCTRNY; (SEQ ID NO.: 11)  
(h) EKKYLWGFTL; (SEQ ID NO.: 12)  
(i) VLATKLRETNAGRCDTQQYRKLLK; or (SEQ ID NO. 13)  
(j) a fragment (i.e., a portion at least six  
35 residues long, but less than all) or analog of (a) - (i)

- 6 -

which is capable of binding parathyroid hormone or parathyroid hormone-related protein [wherein "analog" denotes a peptide having a sequence at least 50% (and preferably at least 70%) identical to the peptide of 5 which it is an analog]. Preferably, the polypeptide of the invention is produced by expression of a recombinant DNA molecule or is synthetic (i.e., assembled by chemical rather than biological means). The invention provides a method for producing such a polypeptide, which method 10 includes providing a cell containing isolated DNA encoding a cell receptor of the invention or receptor fragment and culturing this cell under conditions which permit expression of a polypeptide from the isolated DNA.

The invention also features an antibody 15 (monoclonal or polyclonal), and a purified preparation of an antibody, which is capable of forming an immune complex with a cell receptor of the invention (preferably a parathyroid hormone receptor such as a human PTH receptor) such antibody being generated by using as 20 antigen either (1) a polypeptide that includes a fragment of the cell receptor of the invention, or (2) a cell receptor of the invention which is on the surface of a cell. This antibody is preferably capable of neutralizing (i.e., partially or completely inhibiting) a 25 biological activity of the cell receptor of the invention (i.e., a component of one of the cascades naturally triggered by the receptor when its ligand binds to it). In preferred embodiments, the antibody of the invention is capable of forming an immune complex with parathyroid 30 hormone receptor and is capable of neutralizing a biological activity of the PTH receptor (i.e. adenylate cyclase activation or phospholipase C stimulation)

Also within the invention is a therapeutic composition including, in a pharmaceutically-acceptable 35 carrier, (a) a cell receptor of the invention, (b) a

- 7 -

polypeptide containing a fragment of the cell receptor of the invention, or (c) an antibody to a cell receptor of the invention. These therapeutic compositions provide a means for treating various disorders characterized by  
5 overstimulation of the cell receptors of the invention by their ligand. In preferred embodiments, the polypeptides of the invention include the PTH receptor, fragments of the PTH receptor and antibodies which form immune complexes with the PTH receptor. These polypeptides and  
10 antibodies are useful as diagnostics, for distinguishing those cases of hypercalcemia related to PTH or PTHrP from those which are not.

The nucleic acid probes of the invention enable one of ordinary skill in the art of genetic engineering  
15 to identify and clone cell receptor homologs or cell receptors from any species which are related to the cell receptors of the invention, expanding the usefulness of the sequences of the invention.

Other features and advantages of the invention  
20 will be apparent from the following description of the preferred embodiments and from the claims.

#### Detailed Description

The drawings will first be briefly described.

#### DRAWINGS

25 FIG. 1 is a representation of the nucleic acid and amino acid sequence encoding the opossum kidney PTH/PTHrP receptor clone, OK-H. (SEQ ID NO.: 1)

FIG. 2 is a representation of the nucleic acid and amino acid sequence encoding the opossum kidney PTH/PTHrP  
30 receptor clone, OK-O. (SEQ ID NO.: 2)

FIG. 3 is a representation of the nucleic acid and amino acid sequence encoding the rat bone PTH/PTHrP receptor clone, R15B. (SEQ ID NO.: 3)

- 8 -

FIG. 4 is a comparison of the deduced amino acid sequences encoded by cDNAs from clones OK-O and R15B.

FIG. 5 is a comparison of the deduced amino acid sequences of OK-O, OK-H and R15B, lined up according to sequence homology.

FIG. 6 is a representation of the nucleic acid and amino acid sequence encoding the human PTH/PTHrP receptor. (SEQ ID NO.: 4)

FIG. 7 is a schematic representation of the rat bone PTH/PTHrP receptor cDNA, the human genomic DNA clone HPG1 and two cDNA clones encoding the human PTH/PTHrP receptor.

FIG. 8 is a hydrophobicity plot of the deduced amino acid sequence of the human kidney PTH/PTHrP receptor. Predicted membrane-spanning domains I through VII are indicated; A, B and C indicate additional hydrophobic regions.

FIG. 9 is a graph illustrating binding of PTHrP to COS cells transfected with OK-H.

FIG. 10 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with OK-H.

FIG. 11 is a graph illustrating binding of PTHrP to COS cells transfected with OK-O.

FIG. 12 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with OK-O.

FIG. 13 is a graph illustrating binding of PTHrP to COS cells transfected with R15B.

FIG. 14 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with R15B.

FIG. 15 is a graph illustrating stimulation of inositol phosphate metabolism by NlePTH in COS cells transfected with OK-H, OK-O, or R15B.

- 9 -

FIG. 16 is a graph illustrating cyclic AMP accumulation in COS cells transfected with CDM-8, OK-H, R15B by NlePTH.

FIG. 17 are graphs illustrating binding of  $^{125}\text{I}$ -labelled PTH(1-34) (A and B) and  $^{125}\text{I}$ -labelled PTHrP(1-36) (C and D) to COS-7 cells transiently expressing the human kidney (A and C) and the rat bone (B and D) PTH/PTHrP receptor; competing ligands included PTH(1-34) ( $\square$ ), PTHrP(1-36) (\*), PTH(3-34) ( $\blacksquare$ ), PTH(7-34) (+). Data are given as % specific binding and represent the mean $\pm$ SD of at least three independent experiments.

FIG. 18 is a bar graph illustrating stimulated accumulation of intracellular cAMP in COS-7 cells transiently expressing the human kidney receptor. Data show the mean $\pm$ SD, and are representative of at least three independent experiments.

FIG. 19 represents a Northern blot analysis of total RNA (~ 10  $\mu\text{g}$ /lane) prepared from human kidney (A) and SaOS-2 cells (B). The blot was hybridized with the full length cDNA encoding the human kidney PTH/PTHrP receptor; positions of 28S and 18S ribosomal RNA bands are indicated.

FIG. 20 represents a Southern blot analysis of human genomic DNA digested with SstI, HindIII, and XhoI (~ 10 $\mu\text{g}$ /lane). The blot was hybridized with the full length cDNA encoding the human kidney PTH/PTHrP receptor.

FIG. 21 is a schematic diagram of the proposed arrangement, in a cellular membrane, of PTH/PTHrP rat bone receptor encoded by R15B.

30

#### MATERIALS AND METHODS

GENERAL: [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(1-34)amide (PTH(1-34)), [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(3-34)amide (PTH(3-34)), and [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(7-34)amide (PTH(7-34)) were obtained from Bachem Fine Chemicals, Torrance, CA; [Tyr<sup>36</sup>]PTHrP(1-

- 10 -

36)amide (PTHrP(1-36)) was synthesized as described (Keutman et al., Endocrinology 117:1230, 1985) using an Applied Biosystems Synthesizer 420A. Dulbecco's modified Eagles medium (DMEM), EDTA/trypsin, and gentamycin were from GIBCO (Grand Island, NY); fetal bovine serum (FBS) was from Hyclone Laboratory, Logan, UT. Total RNA from human kidney was provided by Per Hellman, University Hospital, Uppsala, Sweden. Oligonucleotide primers were synthesized using an Applied Biosystems 380B DNA Synthesizer. Restriction enzymes, Klenow enzyme, T4 polynucleotide Kinase and T4 DNA ligase were from New England Biolabs, Beverly, MA. Calf alkaline phosphatase was from Boehringer Mannheim, Germany. All other reagents were of highest purity available.

#### 15 CELLS

Cell lines used include COS cells, OK cells, SaOS-2 cells, CHO cells, AtT20 cells, LLC-PK1 cells, and UMR-106 cells, which are available from a variety of sources including the American Type Culture Collection (Rockland, Maryland), Accession Nos. CRL1650, CRL6551, HTB85, CCL61, CCL89, CL101, and CRL1161, respectively. ROS 17/2 and ROS 17/2.8 are available from a number of sources including Dr. Gideon Rodan (Merck Laboratories, West Point, PA). MC-3T3 cells are derived from mouse bone cells and are also available from a number of sources including Dr. Chohei Shigeno (Dept. of Biochem. Medicine, Hyoto Univ., Kyoto, Japan).

All cells were grown in a humidified 95% air, 5% CO<sub>2</sub> atmosphere and maintained in monolayer culture with Ham's F-12 or DMEM medium (Grand Island Biological Co.), supplemented with 5% or 10% fetal calf serum (M.A. Bioproducts, Walkersville, MD). The medium was changed every 3 or 4 days, and the cells were subcultured every 2 or 3 weeks by

- 11 -

trypsinization using standard methods.

#### CLONING

Isolation of cDNA clones encoding the rat and opossum PTH/PTHrP receptors: Total RNA was initially  
5 isolated from rat osteosarcoma (ROS) cells (ROS 17/2.8) and opossum kidney (OK) cells, by standard methods using guanidium isothiocyanate (Ullrich et al., Science 196: 1313, 1977; Chirgwin et al. Biochemistry 24: 5294, 1979), and centrifugation through cesium chloride (Gilsen et  
10 al., Biochemistry 13: 2633, 1974). Poly A+ RNAs (mRNAs) were then recovered after passage of the total RNAs over oligo dT columns (Pharmacia, Piscataway, NJ) by the method of Aviv and Leder (Proc. Natl. Acad Sci. USA 69: 14087, 1972). The cDNA library from the ROS 17/2.8 mRNA  
15 was prepared from poly A+ RNA using the method of Gubler and Hoffman (Gene (Amst.) 25: 263, 1983). Oligo dT-primed and random-primed cDNAs were synthesized from poly A+ ROS 17/2.8 and OK cell mRNA, respectively (Aviv and Leder, supra). The cDNAs were ligated to BstX1 linkers  
20 (Invitrogen, San Diego, CA) and size-selected by centrifugation (3 h, 55,000 xg) in a 5-20% potassium acetate gradient. The size-selected cDNA was then inserted into the plasmid vector, pCDNA I (Invitrogen), using the non-self annealing BstX1 restriction sites.  
25 The resultant plasmid libraries were then used to transform E. coli (MC1061/P3, Invitrogen) containing a larger helper plasmid, p3. The p3 plasmid possesses amber mutations in two genes which code for ampicillin and  
30 tetracycline resistance. Using ampicillin and tetracycline selection, only those cells containing both the p3 and a tRNA suppressor gene, which is contained within pCDNA I, were capable of growth. The transformed bacteria were then grown to confluence, and the plasmid  
35 DNAs isolated using standard techniques (e.g., see

- 12 -

Ausebel et al., Current Protocols in Molecular Biology, John Wiley Sons, New York, 1989). These DNAs were then taken up in a DEAE-dextran solution, and used to transfect African Green Monkey kidney (COS) cells, which  
5 had been grown to 75% confluence in "sideflasks" (Nunc, Denmark).

Screening for COS cells containing plasmids capable of expressing functionally-intact ROS or OK cell parathyroid hormone/parathyroid hormone related-protein  
10 (PTH/PTHrP) receptor proteins was performed according to Gearing et al. (EMBO J. 8: 3676, 1989), with some minor modifications including DEAE-Dextran transfection in sideflasks. Forty-eight hours after transfection, the cells were tested for binding of <sup>125</sup>I-labeled [Tyr<sup>36</sup>]PTHrp  
15 (1-36) amide, using methods previously described (Yamamoto et al., Endocrinology 122: 1208, 1988), with the following exceptions: the time and temperature of the incubation were 2h and room temperature, respectively. After rinsing, the cells were fixed with 1.25%  
20 glutaraldehyde, and rinsed with 1% gelatin. After snapping off the top of the sideflask, the remaining microscope slide was dipped into NTB-2 photographic emulsion (Eastman Kodak, Rochester, NY). After 3-4 days of exposure at 4°C, the slides were developed, fixed, and  
25 stained with 0.03% toluidine blue. Screening of each slide was performed under a light microscope (Olympus). One pool of plasmid-DNA from ROS cells, and two pools of plasmid-DNA from OK cells, (10,000 independent clones), each gave rise to 3-4 transfected COS cells expressing  
30 the PTH/PTHrP receptor. These pools were subsequently subdivided. The subpools were used to transfect COS cells, and single clones were identified that expressed receptor protein capable of binding the radioligand.

Isolation of cDNA and genomic DNA clones encoding  
35 the human PTH/PTHrP receptor: A human kidney oligo dT-

- 13 -

primed cDNA library ( $1.7 \times 10^6$  independent clones) in  
lambda GT10 and a genomic library of human placental DNA  
( $2.5 \times 10^6$  independent clones) in EMBL3 (Sp6/T7) (Clontech,  
Palo Alto, CA) were screened by the plaque hybridization  
5 technique (Sambrook et al., Molecular Cloning: A  
Laboratory Manual, 2nd Ed. pp. 108-113, Cold Spring  
Harbor Laboratory, Cold Spring Harbor, NY, 1989) with the  
 $^{32}\text{P}$ -labelled (random primed labelling kit Boehringer  
Mannheim, Germany) BamHI/NotI 1.8kb restriction enzyme  
10 fragment encoding most of the coding sequence of the rat  
bone PTH/PTHrp receptor (Fig. 3). The nitrocellulose  
filters were incubated at  $42^\circ\text{C}$  for 4 hrs in a  
prehybridization solution containing 50% formamide, 4x  
saline sodium citrate (SSC;  $1\times$  SSC: 300 mM NaCl, 30 mM  
15 NaCitrate, pH 7.0), 2x Denhardt's solution,  
10% Dextran sulphate, 100  $\mu\text{g}/\text{ml}$  salmon sperm DNA (final  
concentration). The hybridizations were carried out in  
the same solution at  $42^\circ\text{C}$  for 18-24h. Filters were  
washed with 2x SSC/0.1% SDS for 30 minutes at room  
20 temperature and then with  $1\times$  SSC/0.1% SDS for 30 minutes  
at  $45^\circ\text{C}$ . The films were exposed at  $-80^\circ\text{C}$  for 18-24h using  
intensifying screens.

About 1,000,000 clones were screened from each  
library. Positive clones were plaque-purified and lambda  
25 phage DNA was isolated (Sambrook et al., *supra*). Cloned  
inserts were removed from phage DNA by digestion with  
restriction endonucleases HindIII and EcoRI (lambda GT10  
library), or with XhoI and SstI (EMBL3 library), and were  
then subcloned into pcDNAI (Invitrogen, San Diego, CA)  
30 using the appropriate, dephosphorylated restriction  
sites. Sequencing of the  $\text{CsCl}_2$ -purified subclones was  
performed according to Sanger et al. (Biochem 74:5463,  
1977) by the dideoxy termination method (Sequenase  
version 2 sequencing kit, United States Biochemical  
35 Corporation, Cleveland, OH).

- 14 -

reaction (PCR): 3 µg of poly (A)+ RNA from human kidney (Clontech, Palo Alto, CA) in 73.5 µl of H<sub>2</sub>O was incubated at 100°C for 30 seconds, quenched on ice, and then added to 20 µl of 5x RT buffer (1x RT buffer: 40 mM Tris-HCl, pH 8.2, 40 mM KCl, 6.6 mM MgCl<sub>2</sub>, 10 mM dithiothreitol, and dNTPs at 0.5 mM each), 2 µl (4 units) RNasin (Promega Biotec, Madison, WI), 1 µl (80 pmo/µl ) of the human cDNA primer H12

10 (5'-AGATGAGGCTGTGCAGGT-3'; SEQ ID NO.: 14) and 80 units of avian myeloblastosis virus reverse transcriptase (Life Sciences, St. Petersburg, FL). The reaction mixture was incubated for 40 minutes at 42°C. One-tenth of the first strand synthesis reaction mixture was then amplified by  
15 PCR in a final volume of 100 µl containing 3 mM MgSO<sub>4</sub>, 200 µM dNTPs, 2 units of Vent polymerase (New England Biolab, Beverly, MA), and 2 µM each of the forward and the reverse primers (PCR conditions: denaturing for 1 min at 94°C, annealing for 1 min at 50°C, and extension at  
20 72°C for 3 minutes; 40 cycles).

Two independent PCRs were performed using two different forward primers: i) degenerate primer RK-1 (5'-GGAATTCCATGGGAGCGGCCCGGAT-3'; SEQ ID NO.: 15) based on  
the 5' coding end of the two previously cloned PTH/PTHrP receptors (described above), and ii) primer RK-2 (5'-CGGGATCCC G CGGCCCTAGGCGGT-3'; SEQ ID NO.: 16) based on the 5' untranslated region of the human genomic clone HPG1. Both PCR reactions used the reverse primer H26 (5'AGTATAGCGTCCTTGACGA-3'; SEQ ID NO.: 17) representing nucleotides 713 to 731 of the coding region of the human PTH/PTHrP receptor (Fig. 4). PCR products were blunt-ended using Klenow enzyme and cloned into dephosphorylated pCDNAI cut with EcoRV.

- 15 -

Northern blot analysis: Total RNA was extracted from SaOS-2 cells and from human kidney by the guanidine thiocyanate method (Chirgwin et al., Biochem. 18:5294, 1979). For Northern blot analysis, ~10 µg of total RNA  
5 was subjected to electrophoresis on a 1.5%/37% formaldehyde gel and blotted onto nitrocellulose filters (Schleicher and Schuell, Keene, NH). The hybridization conditions were the same as those for screening the phage libraries (see above). The filters were washed at a final  
10 stringency of 0.5x SSC/0.1% SDS for 30 min at 60°C and exposed for autoradiography.

Southern blot analysis: Human genomic DNA was prepared using the SDS/proteinase K method (Gross-Bellard et al., Eur. J. Biochem. 36:32, 1973). For Southern  
15 analysis, ~10 µg of DNA was digested with SstI, PvuII and XhoI; subjected to electrophoresis on a 0.8% agarose gel; and blotted onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH). The hybridization conditions were the same as those for screening the phage libraries (see  
20 above). The filters were washed at a final stringency of 0.5x SSC/0.1% SDS for 30 min at 55°C and exposed for autoradiography.

#### FUNCTIONAL ASSAYS

Tests to characterize the functional properties of  
25 the cloned receptors expressed on COS cells included:

- I) binding of PTH and PTHrP fragments and analogues,
- II) stimulation of cyclic AMP accumulation by PTH and PTHrP fragments and analogues,
- III) increase of intracellular free calcium by PTH  
30 and PTHrP fragments and analogues, and
- IV) activation of inositol phosphate metabolism by PTH and PTHrP fragments and analogues. The methodologies are as follows:

- 16 -

Radioreceptor Assay

[Nle<sup>8</sup>,Nle<sup>18</sup>,Tyr<sup>34</sup>]bPTH-(1-34)amide (NlePTH), and [Tyr<sup>36</sup>]PTHrP(1-36)amide(PTHrP) were iodinated with Na<sup>125</sup>I (carrier free, New England Nuclear, Boston, MA) as previously reported (Segre et al., J. Biol. Chem. 254: 6980, 1979), and purified by reverse-phase HPLC. In brief, the labeled peptide was dissolved in 0.1% trifluoroacetic acid (TFA), applied to a C<sub>18</sub> Sep-pak cartridge (Waters Associates, Inc., Milford, MA) and eluted with a solution of 60% acetonitrile in 0.1% TFA. After lyophilization, the radioligand then was applied to C<sub>18</sub>-μBondapak column (3.9 mm x 30 cm. Waters Associates) and eluted over 30 min with a linear gradient of 30-50% acetonitrile-0.1% TFA at a flow rate of 2 ml/min. The radioligand eluted in two peaks; the first peak, which eluted at approximately 38% acetonitrile, was used in these studies because it gave higher total and specific bindings. The specific activity was 500 ± 75 mCi/mg, which corresponds to an average iodine-peptide ratio of 1.

COS-7 cells were grown in 15 cm plates in DMEM, 10% heat-inactivated FBS, 10 mg/L gentamycin until 80-90% confluent. Twenty-four hours after transfection by the DEAE/Dextran method (Sambrook et al., *supra*), with 1-2 μg of plasmid DNA, the cells were trypsinized and replated in multiwell plastic dishes (16 or 35 mm diameter, Costar, Cambridge, MA) at a cell concentration of 5 x 10<sup>4</sup> cells/cm<sup>2</sup>). Cell number increased only slightly after transfection. After continuing culture for another 48 h, radioreceptor assays were performed. The culture medium was replaced with buffer containing 50 mM Tris-HCL (pH 7.7), 100 mM NaCl, 2 mM CaCl<sub>2</sub>, 5 mM KCL, 0.5% heat-inactivated fetal bovine serum (GIBCO), and 5% heat-inactivated horse

- 17 -

serum (KC Biological Inc., Lenexa, KS) immediately before studies were initiated. Unless otherwise indicated, studies were conducted with cells incubated in this buffer at 15°C for 4 h with  $4 \times 10^5$  cpm/ml ( $9.6 \times 10^{-11}$  M) of  $^{125}\text{I}$ -labeled NlePTH or PTHrP.

Incubations were terminated by aspirating the buffer, and repeatedly (x3) washing the culture dishes containing the adherent cells with chilled 0.9% NaCl solution, over a 15 sec period. Cell-bound radioactivity was recovered by the sequential addition (x3) of 1 N NaOH (200  $\mu\text{l}$ ) to each well. After 30 min at room temperature, the NaOH was transferred to a glass tube. A second and third extraction with 1 N NaOH (200  $\mu\text{l}$ ) were combined with the first, and the total radioactivity was counted in a  $\gamma$ -spectrometer (Packard Instruments, Downers Grove, IL). Tracer adherence to culture vessel without cells was negligible (<0.2% of total counts added), if vessels were preincubated with culture medium.

#### Determinations of cAMP accumulation

Intracellular cAMP accumulation was measured as described previously (Abou-Samra et al., J. Biol. Chem. 262:1129, 1986). Cells in 24-well plates were rinsed with culture medium containing 0.1% BSA and 2mM IBMX. The cells were then incubated with PTH or PTHrP for 15 min. at 37° C. The supernatant was removed and the cells immediately frozen by placing the whole plate in dry ice powder. Intracellular cAMP was extracted by thawing the cells in 1ml of 50 mM HCl and analyzed by a specific radioimmunoassay using an anti-cAMP antibody (e.g., Sigma, St. Louis, MO). A cAMP analog (2'-O-monosuccinyl-adenosine 3':5'-cyclic monophosphate tyrosyl methyl ester, obtained from Sigma) which was used a tracer for cAMP was iodinated by the chloramine T method. Free iodine was removed by adsorbing the iodinated cAMP analog onto a C18 Sep-pak cartridge (Waters, Milford, MA).

- 18 -

After washing with  $\text{dH}_2\text{O}$ , the iodinated cAMP analog was eluted from the Sep-pak Cartridge with 40% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). The iodinated cAMP analog was lyophilized, reconstituted in 1 ml 0.1% TFA, and injected into a C18 reverse phase HPLC column (Waters). The column was equilibrated with 10% ACN in 0.1% TFA, and eluted with gradient of 10-30% ACN in 0.1% TFA. This allows separation of the mono-iodinated cAMP analog from the non-iodinated cAMP analog. The tracer is stable for up to 4 months when stored at  $-20^\circ\text{C}$ . The standard used for the assay, adenosine 3':5'-cyclic monophosphate, was purchased from Sigma. Samples (1-10  $\mu\text{l}$  of HCl extracts) or standards (0.04-100 fmol/tube) were diluted in 50 mM Na-acetate (pH 5.5), and acetylated with 10  $\mu\text{l}$  of mixture of triethylamine and acetic anhydride (2:1 vol:vol). After acetylation, cAMP antiserum (100  $\mu\text{l}$ ) was added from a stock solution (1:4000) made in PBS (pH 7.4), 5 mM EDTA and 1% normal rabbit serum. The tracer was diluted in PBS (pH 7.4) with 0.1% BSA, and added (20,000 cpm/tube). The assay was incubated at  $4^\circ\text{C}$  overnight. The bound tracer was precipitated by adding 100  $\mu\text{l}$  of goat anti-rabbit antiserum (1:20 in PBS) and 1 ml of 7% polyethyleneglycol (MW 5000-6000), centrifuging at 2000 rpm for 30 min. at  $4^\circ\text{C}$ . The supernatant was removed and the bound radioactivity was counted in a  $\gamma$ -counter (Micromedic). Standard curves were calculated using the four-parameter RIA program supplied by Micromedic. Typically, the assay sensitivity is 0.1 fmol/ tube, and the standard concentration that displaces 50% of tracer is 5 fmol/tube.

In an alternative method for assaying cAMP accumulation, COS cells transfected with PTH/PTHrP receptor cDNA are harvested with a plastic policeman into a solution containing 10 mM Tris-HCl (pH 7.5), 0.2 mM

- 19 -

MgCl<sub>2</sub>, 0.5 mM ethyleneglycolbis( $\beta$ -amino ethyl ether) *N,N'*-tetra-acetic acid (EGTA) (Sigma) and 1 mM dithiothreitol (Sigma). Cells are homogenated by 20 strokes of tightly-fitting Dounce homogenizer, and centrifuged at 13,000 x g for 15 min at 4°C (Eppendorf, type 5412, Brinkmann Instruments, Inc., Westburg, NY). The pellet containing the plasma membranes is resuspended in the same buffer by several strokes with a Dounce homogenizer, and further diluted with the same buffer to a protein concentration of approximately 1.2 mg/ml, as determined by the method of Lowry et al. (Lowry et al., J. Biol. Chem 193: 265, 1951). Approximately 30  $\mu$ g (25  $\mu$ l) membrane are incubated with varying concentrations of hormone or vehicle alone for 10 min at 37°C (final volume, 100  $\mu$ l) in 50 mM Tris-HCl (pH 7.5), 0.8 mM ATP, 4 x 10<sup>6</sup> cpm [ $\alpha$ -<sup>32</sup>P] ATP (New England Nuclear, Boston, MA), 9 mM theophylline, 4.2 mM MgCl<sub>2</sub>, 26 mM KCl, 0.12% BSA, and an ATP-regenerating system containing 5 mM creatine phosphate (Schwartz/Mann Division, Becton-Dickenson & Co., Orangeburg, NY) and 0.1 mg/ml creatine phosphokinase (Schwartz/Mann). Incubations are initiated by addition of the membrane suspension and terminated by addition of 100  $\mu$ l of a solution containing 20 mM cAMP, approximately 50,000 cpm [<sup>3</sup>H]cAMP, and 80 mM ATP. The reaction mixture is boiled, and the [<sup>32</sup>P]cAMP generated is purified by sequential chromatography on ion-exchange columns (Dowex 50 W-X4, Biorad Lab, Richmond, CA) and alumina (Sigma). The [<sup>32</sup>P]cAMP may be counted in a  $\beta$ -scintillation counter (Packard Instrument Co.), with correction for recovery of [<sup>3</sup>H]cAMP.

#### Determination of intracellular free calcium

Measurements of intracellular calcium levels in cells transfected with PTH/PTHrP receptor cDNAs were performed using Fura-2 AM (acetomethoxy ester of Fura-2,

- 20 -

Molecular Probes Inc., Eugene, OR) loaded cells. Details of the methodology are:

- Coverslips plated with COS cells were incubated in Fura-2 AM loading buffer containing, in mM: HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]), 20;  $\text{CaCl}_2$ , 1; KCl 5; NaCl, 145;  $\text{MgSO}_4$ , 0.5;  $\text{NaHCO}_3$ , 25;  $\text{K}_2\text{HPO}_4$ , 1.4; glucose, 10; and Fura-2 AM 91-(2'-5'-carboxyoxazol-2'-yl)-6-aminobenzofuran-5-oxy-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid acetomethoxy ester), 0.5; at 37°C at pH7.4, aerated with 95% air and 5%  $\text{CO}_2$  for 45 minutes. Cells loaded with Fura-2 AM were then washed with a modified Krebs-Heinseleit (KH) buffer containing, in mM: HEPES, 20;  $\text{CaCl}_2$ , 1; KCl, 5; NaCl, 145;  $\text{MgSO}_4$ , 0.5;  $\text{Na}_2\text{HPO}_4$ , 1; glucose, 5; pH7.4. To check that cleavage of the ester occurred, the excitation spectra after different times of Fura-2 AM incubation were measured. At 5 min. after the start of incubation, the excitation spectrum peaked at approximately 360 nm, reflecting incomplete hydrolysis of Fura-2 AM, whereas beyond 30 min. the excitation spectrum peaked at 345 nm, characteristic of Fura-2.

- To measure fluorescence of individual cells, the cover slips were placed in a microscope tissue chamber (Biophysica Technologies, Inc., MD). The chamber consisted of a shallow, sloped compartment made of Teflon with a silicone rubber seal. The cover slips served as the bottom of the chamber. A heater/cooler ring was encased in the silicone rubber which sealed the coverslip in place. Temperatures were varied between 22°C and 37°C by applying 0-7.4 V to the heater. If the temperature is not specifically stated, the experiment was performed at 37°C. The chamber was mounted on the stage of an inverted microscope (Zeiss IM-35, Thornwood, NY). Fura-2 fluorescence was excited with a 75 watt Xenon arc lamp placed at the focal point of a condenser (Photon

- 21 -

Technologies International (PTI) Inc., NJ). Grating monochromators, alternated by a rotating chopper in which mirror vanes alternate with transmitting sectors, were used for selecting wavelengths. The monochromator outputs were combined to form a common optical path which exited the source housing through an adjustable iris. The light then passed through quartz lenses and a dichroic mirror through a 100x Nikon Fluor objective. A photon-counting PMT device detection was used to measure the light output. Data analysis was performed using PTI software run on an IBM-compatible AT/286 computer using the MS-DOS operating system. Data was retained and manipulated in a packed binary format.

Intracellular calcium concentrations were calculated according to the formula:  $[Ca^{2+}]_i = K_d(R - R_{min}) / (R_{max} - R)B$ , where R is the ratio of fluorescence of the cell at 340 and 380 nm;  $R_{max}$  and  $R_{min}$  represent the ratios of Fura-2 fluorescence intensity at 340 and 380 nm excitation wavelengths in the presence of a saturating amount of calcium and effectively zero calcium, respectively; B is the ratio of fluorescence of Fura-2 at 380 nm in zero calcium to that in saturating amounts of calcium; and  $K_d$  is the dissociation constant of Fura-2 for calcium. To determine  $R_{max}$ , at the end of an experiment ionomycin was added to the Fura-2 AM loaded cells to equilibrate  $Ca^{2+}$  between the extracellular (1mM) and intracellular environments. To calculate  $R_{min}$ , 1mM EGTA was then added to the bathing solution. Different dissociation constants were used at the different temperatures: 224 nM at 34-37°C and 135 nM at 24-27°C.

#### Determination of inositol phosphate

The level of inositol phosphate metabolism was determined in COS cells transfected with PTH/PTHrP

- 22 -

receptors using previously published methods (Bonventre, et al., J. Biol. Chem. 265: 4934, 1990).

## RESULTS

### Molecular characterization

5 Two independent clones (OK-H and OK-O), both of which were isolated from the OK cell cDNA library, had lengths of approximately 2 kilobases. The determined nucleotide sequence and predicted amino acid sequence of these clones are shown in Figs. 1 (SEQ ID NO.:1) and 2  
10 (SEQ ID NO.:2) respectively. The R15B clone isolated from the ROS cell cDNA library had a length of approximately 4 kilobases. The determined nucleotide sequence and predicted amino acid sequence of the rat bone PTH/PTHrP receptor is depicted in Fig. 3 (SEQ ID  
15 NO.:3).

The three cDNA clones appear to be full-length by the criteria of having codons encoding methionine residues that are predicted to be the likely candidates as initiator methionines. These methionine codons are  
20 followed by amino acid sequences (deduced from the DNA) with properties suggesting that they are "signal-peptide" sequences. All three receptor cDNAs have stop codons at locations that permit these receptors to "fit" a putative seven-membrane spanning model, a model typical for G-  
25 protein-linked receptors. Most importantly, all three cloned receptors bind ligands and, when activated, are capable of activating intracellular effectors. These properties suggest that all three of the isolated clones encode full-length cDNAs.

30 Fig. 4 demonstrates the high degree of homology between the amino acid sequences encoded by the cDNAs from OK-O and ROS 15B. There is an overall 87% homology and a 77.8% amino acid identity between these two receptors. This high level of identity over long

- 23 -

stretches of amino acids demonstrates that the amino acid sequence of the PTH receptor is evolutionarily conserved to a high degree. This allows the data from both OK-O and R15B to be extrapolated to other species, including  
5 human.

Fig. 5 shows the deduced amino acid sequences of all three cloned cDNAs lined up according to sequence homology. The OK-H sequence is identical to OK-O except in the C-terminus tail, where the OK-O sequence totals  
10 585 amino acids whereas the OK-H sequence stops at 515 amino acids. This difference is attributable to a single nucleotide (G) deleted in the OK-H sequence compared to the OK-O sequence, causing a frame shift and early stop codon in the former. It is not known whether OK-O and  
15 OK-H represent the products of two separate genes or of a laboratory artifact.

Some G-protein-coupled receptors are encoded by intronless genes (Kobilka et al., *Nature* 329:75, 1987); Kobilka et al., *J. Biol. Chem.* 262:7321, 1987; Heckert et al., *Mol. Endocrinol.* 6:70, 1992; Kobilka et al., *Science* 238:650, 1987; Bonner et al., *Science* 237:527, 1987; Sunahara et al., *Nature* 347:80, 1990). To isolate a human PTH/PTHrP receptor cDNA, both a human cDNA library and a human genomic library were screened with a probe  
20 (BamHI/NotI) representing most of the coding region of the rat bone PTH/PTHrP receptor (Fig. 3). Screening the human kidney cDNA library led to the isolation of the clone HK-1 (Fig. 6) [SEQ ID NO.: 6]. Since one of the two EcoRI cloning sites of lambda GT10 proved to be  
25 eliminated as a result of the library construction, the HindIII/EcoRI phage fragment containing the cDNA insert and ~250 bp of the 37 kb (left) lambda arm was subcloned into the corresponding restriction sites in pCDNAI. DNA sequencing revealed that the cloned cDNA contained ~1000  
30 bp of the 3' coding region and ~200 bp of the 3' non-

- 24 -

coding region including an A-rich 3' end. The coding region 5' to the XhoI site was subsequently used to re-screen the library and led to the isolation of the clone HK-2 which, after subcloning into pcDNAI, proved to contain ~1400 bp of the coding region. For the third screening of the library, the PvuII/PstI fragment of HK-2 was used; the isolated clone HK-3 proved to be identical to HK-2.

The genomic library screening ( $\sim 10^6$  pfu) resulted in the isolation of four independent clones. Comparison of Southern blot analyses of restriction enzyme digests of these clones with that of normal genomic DNA, revealed that one 15 kb genomic clone, HPG1 (also referred to as HG4A), contained a SstI/SstI fragment that had the same size as one hybridizing DNA species from normal human genomic DNA digested with SstI (see below). The hybridizing 2.3 kb SstI/SstI DNA fragment and an ~8 kb XhoI fragment which comprised the SstI/SstI fragment were both subcloned into pcDNAI. Further Southern blot analysis of the SstI/SstI DNA fragment revealed that an ~1000 bp BamHI/SstI fragment encoded a portion of the human PTH/PTHrP receptor which later proved to represent the exon encoding the putative signal peptide and the 5' non-translated region which is interrupted by an ~1000 bp intron (Fig. 7).

To isolate the remaining ~450 nucleotides of the coding region, poly (A)+ RNA from human kidney was reverse transcribed after priming with H12 (Fig. 7). After single strand synthesis, two independent PCRs were performed using two different forward primers: i) a degenerate primer RK- 1 based on the 5' coding end of the two previously cloned PTH/PTHrP receptors, OK-O and R15B; and ii) primer RK-2 based on the 5' non-coding region of HPG1. H-26 was used as the reverse primer for both reactions. Southern blot and restriction map analyses

- 25 -

confirmed the expected size of the amplified DNA encoding the human PTH/PTHrP receptor. The blunt-ended PCR products encoding the 5' end of the human PTH/PTHrP were cloned into pcDNA1 using the dephosphorylated EcoRV sites. Sequence analysis of each PCR clone confirmed their 5' nucleotide difference due to the difference in forward primer sequence, but revealed otherwise identical sequences. Nucleotide sequencing of both strands of the human PTH/PTHrP receptor cDNA revealed an open reading frame encoding a 593-amino acid protein (Fig. 6, SEQ ID NO.:4).

The full-length human kidney PTH/PTHrP receptor cDNA, HKrk, was constructed using the BamHI/PvuII fragment of PCR clone #2 and HK-2. Using the full-length cDNA encoding the human PTH/PTHrP receptor, Northern blot analysis of total RNA (~10 µg/lane) from human kidney and SaOS-2 cells revealed one major hybridizing DNA species of ~2.5 kb (Fig. 19). The XhoI digest of normal human genomic DNA, when probed with the same full-length cDNA (Fig. 20), revealed one major hybridizing species of about 5.5 kb, and two DNA species of 4 and 8 kb which weakly hybridized. These data suggest that the human PTH/PTHrP receptor is the product of a single gene. This full-length clone was then transiently expressed in COS-7 cells for functional and biological characterization by the methods cited above.

Comparison of the human receptor with the opossum kidney PTH/PTHrP receptor and the rat bone PTH/PTHrP receptor, revealed 81% and 91% amino acid sequence identity, respectively, and consequently a very similar hydrophobicity plot (Fig. 8). All extracellular cysteines including the two cysteine residues in the presumed signal peptide are conserved, as are all potential, extracellular

- 26 -

N-glycosylation sites. A number of the amino acids which were not identical between the human kidney and rat bone PTH/PTHr receptors were found to be conserved between the human and the opossum receptors. These conserved amino acids include an Arg to Leu at 51, an Arg to Trp at 58, an Arg to His at 262, an Asp to His at 358, an Ile to Thr at 422, and a Thr to Leu at 427.

#### Biological Characterization

Functional characterization of the biological properties of the opossum and rat PTH/PTHrP receptors was performed in transiently transfected COS cells by a radioreceptor assay technique using both  $^{125}\text{I}$ -PTHrP and  $^{125}\text{I}$ -NlePTH as radioligands, and by bioassays that measure ligand-stimulated cAMP accumulation, increase in intracellular free calcium, and stimulation of inositol phosphate metabolism, by the methods cited above.

Fig. 9 demonstrates that COS cells expressing OK-H bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle substitutions for methionine at positions 8 and 18 and a tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors. These data indicate that PTH and PTHrP both bind to the receptor encoded by OK-H.

Fig. 10 demonstrates that COS cells expressing OK-H increase their concentration of intracellular free calcium when exposed to NlePTH, but to a smaller extent (mean = 39 nm), or not at all, when compared to COS cells expressing OK-O or R15B receptors (Fig. 12 and Fig. 14) and stimulated with NlePTH. Unlike COS cells expressing

- 27 -

OK-O or R15B, COS cells expressing OK-H do not show a detectable increase in metabolism of inositol phosphate when stimulated with NlePTH (Fig. 15).

Fig. 11 demonstrates that COS cells expressing OK-  
5 O bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle substitutions for methionine at positions 8 and 18 and a  
10 tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors. These data indicate that PTH and PTHrP both bind to the  
15 receptor encoded by OK-O.

Fig. 12 demonstrates that COS cells expressing OK-O increase their concentration of intracellular free calcium and their rate of inositol phosphate metabolism after stimulation with NlePTH and PTHrP (Fig. 15).

Fig. 13 demonstrates that COS cells expressing  
20 R15B bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle  
25 substitutions for methionine at positions 8 and 18 and a tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors.  
30 These data indicate that PTH and PTHrP both bind to the receptor encoded by R15B.

Fig. 14 demonstrates that COS cells expressing R15B increase their concentration of intracellular calcium to an extent similar to stimulated COS cells  
35 expressing OK-O.

- 28 -

Fig. 15 demonstrates that COS cells expressing R15B or OK-O increase their rate of phosphatidyl inositol hydrolysis, as evidenced by the rapid increase in inositol trisphosphate ( $IP_3$ ) and inositol bisphosphate ( $IP_2$ ) accumulation after stimulation of the cells with NlePTH or PTHrP. Conversely, COS cells expressing OK-H did not show any detectable increase in inositol trisphosphate and inositol bisphosphate accumulation after stimulation with NlePTH or PTHrP. These data suggest that the PTH receptor encoded by R15B and OK-O is coupled to phospholipase C, presumably through  $G_p$ . Since the only difference between OK-O and OK-H is in the cytoplasmic C-terminal tail, these data strongly suggest that the C-terminus of the PTH receptor encoded by OK-O and R15B is involved in the activation of phospholipase C.

Fig. 16 demonstrates that COS cells expressing R15B and OK-H increase cAMP accumulation after stimulation with NlePTH. Similar results were obtained in COS cells expressing OK-O. No cAMP stimulation was detected in COS cells transfected with the cDM8 vector alone. These data suggest that PTH receptor coupling to adenylate cyclase does not require the full length C-terminal cytoplasmic tail of the receptor.

These data demonstrate that all three PTH/PTHrP receptors cloned from both OK and ROS cell cDNA libraries bind the amino-terminal ligands of both peptides equivalently. Activation of all these receptors by ligand stimulates adenylate cyclase (as measured by increased intracellular cAMP), presumably through activation of one class of guanine nucleotide binding proteins (G-proteins). G-proteins have a trimeric peptide structure in which one of the subunits, alpha, is distinct, and the other two, beta and gamma, are identical or highly homologous. One of these G-proteins

- 29 -

(G<sub>s</sub>) contains G-alpha-"stimulatory" (G-alpha-s) which is involved in the activation of adenylate cyclase.

Binding of ligand to OK-O and R15B, but not to OK-H, also increases intracellular free calcium and stimulates metabolism of inositol phosphate. These properties strongly suggest that activation of both OK-O and R15B receptors by ligand results in stimulation of a second intracellular effector, phospholipase C. The coupling mechanism between these activated receptors and phospholipase C is likely to be a G-protein which is distinct from G<sub>s</sub>. In contrast, the properties of the activated OK-H receptor which is truncated at the carboxy terminus, suggest that it may not activate phospholipase C, or that it activates phospholipase C inefficiently.

The biochemical role of the carboxy-terminal tail of the PTH/PTHrP receptor was further investigated by the construction of a carboxy-terminally-truncated rat receptor, R480, by standard PCR technology using R15B as a template and an upstream primer containing a stop codon inserted at position 481. Briefly, the upstream primer was a synthetic oligonucleotide based on nucleotides 1494-1513 of the rat cDNA sequence (see Fig. 3; SEQ ID NO.: 3) to which a stop codon and an XbaI cloning site were added. Thirty PCR cycles were carried out, each cycle consisting of 1 min at 92°C for denaturation, 1 min at 60°C for annealing, and 1 min at 72°C for extension. The product was cut with NsiI and XbaI and purified by gel electrophoresis. R15B was sequentially digested with XbaI and NsiI, and the purified PCR product was then ligated into the XbaI-NsiI cut R15B vector. The resulting plasmid, R480, was amplified in bacteria and sequenced.

R480 encodes 480 amino acids that are identical to those in the 591 amino acids receptor. This truncated cDNA was expressed in COS-7 cells (transient expression)

- 30 -

and in CHO cells (stable expression). Both COS-7 and CHO cells expressing the truncated receptor, R480, and the wild type receptor, RB, bind PTH(1-34) with equivalent affinities. When activated, R480 stimulates cAMP accumulation in COS7 and CHO cells as efficiently as does the wild type receptor. In contrast to the wild type receptor, R480 did not mediate any increase in  $[Ca^{2+}]_i$  when stimulated by PTH in either the COS-7 cells or the CHO cells. These data indicate that the molecular requirements for activation of phospholipase C and adenylyate cyclase by PTH/PTHrP receptor are distinct from each other, and point to a major role of the carboxy-terminal tail of the PTH/PTHrP receptor in coupling to phospholipase C but not to adenylyate cyclase. Of course, it is also possible that activated PTH/PTHrP receptors may activate additional G-proteins and/or intracellular effector molecules.

Analysis of COS-7 cells transfected with the cloned human PTH/PTHrP receptor demonstrated that radiolabelled PTH(1-34) and PTHrP(1-36) (~200,000 cpm) bound to the expressed receptors with similar efficiency (specific binding:  $10.1 \pm 3.7\%$  and  $7.6 \pm 6.0\%$ , respectively) to that observed for COS-7 cells expressing R15B (specific binding:  $8.1 \pm 3.5\%$  and  $7.1 \pm 4.1\%$ , respectively). The expressed human PTH/PTHrP receptors bound PTH(1-34) with 2-fold higher apparent  $K_d$  than did the rat bone PTH/PTHrP receptor: ~5 nM versus ~10 nM (Fig. 17). However, despite their high degree of amino acid homology, the two receptors showed significant differences in affinity for PTH(3-34) and PTH(7-34). PTHrP(1-36) displayed a 2- to 4-fold lower affinity for the human PTH/PTHrP receptor than for the rat receptor (~35 nM for HKrk versus ~10 nM for R15B) which appeared more pronounced when PTHrP(1-36) was used as radioligand. The affinities for PTH(3-34) and PTH(7-34) were 7- and

- 31 -

35-fold higher with the expressed HKrK than with R15B (~7 nM versus ~45 nM for PTH(3-34), respectively; ~60 nM versus ~2000 nM for PTH(7-34), respectively). In COS-7 cells expressing either receptor, both PTH(1-34) and PTHrP(1-36) stimulated the increase in intracellular free calcium and cAMP accumulation to the same extent (Fig. 18).

#### Relationship of PTH/PTHrP receptors

The amino acid sequence of the human PTH/PTHrP receptor displays a very high degree of conservation compared to the bone PTH/PTHrP receptor from rat, a eutherian mammal, while its sequence identity with the PTH/PTHrP receptor with the opossum, a marsupial mammal, is less marked. Like the opossum kidney and the rat bone receptor, the human kidney receptor induces an increase in both intra-cellular cAMP and intracellular free calcium when challenged with either PTH or PTHrP. Despite the high degree of homology between the human PTH/PTHrP receptor and the opossum and rat homologs, the transiently expressed human receptor has some functional characteristics that are distinct from those of the rat bone receptor. These include a slightly higher affinity for PTH(1-34) and a significantly decreased affinity for PTHrP(1-36). Higher affinities were observed for PTH(3-34) and in particular for PTH(7-34), the affinity of which for the human receptor was about 35-fold higher in comparison to the rat bone receptor. These findings may have significant implications for the future development of PTH/PTHrP analogues, since they predict that species-specific tissues would be the appropriate tissues for testing the potency of antagonists (and agonists) in vitro.

#### Relationship of PTH/PTHrP receptors to other receptors

The biochemical properties of PTH and PTHrP receptors suggest that they are members of the class of

- 32 -

membrane receptor molecules known as G-protein-linked membrane receptors. The structural features of well-characterized G-protein receptors indicate that they all have at least seven regions of several consecutive  
5 hydrophobic amino acids, each of which regions is of sufficient length to span the plasma membrane.

One subfamily of G-protein-linked membrane receptors, termed the glycopeptide receptor subfamily, includes receptors that bind and are activated by  
10 glycopeptide hormones (thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and chorionic gonadotropin). All of these receptors are characterized by (1) extensive putative amino-terminal extracellular domains (greater than 300 amino acids) that  
15 are thought to contain some or all of the ligand-binding domains, and (2) considerable amino-acid homology, particularly in the seven putative transmembrane domains. A second subfamily, termed the adrenergic/muscarinic<sup>\*</sup> subfamily, includes receptors that are activated by small  
20 ligands, such as the catecholamines, neuromuscular transmitters, and retinol. These receptors are all characterized by relatively short (25-75 amino acids) putative amino-terminal extracellular domains, as well as considerable amino acid homology, particularly in the  
25 seven putative transmembrane domains. Activation of these receptors by their ligands appears to involve at least several of the multiple transmembrane domains, and does not appear to involve the amino-terminal portion of the receptors.

30 Several structural characteristics which can be deduced from the predicted amino acid sequence of the rat PTH/PTHrP receptor (Fig. 3) indicate that the PTH/PTHrP is a G-protein-linked receptor. The amino terminus shows characteristic features of a signal peptide, including a  
35 hydrophobic domain and the presence of three consecutive

- 33 -

leucine residues. This amino acid stretch of 20-28 amino acids may serve as a leader sequence, similar to the amino terminus preceding the extracellular domains of other glycoprotein receptors. There is also a cluster of  
5 seven hydrophobic segments which represent putative membrane-spanning domains (Fig. 19).

The predicted amino acid sequences of the opossum kidney, rat bone and human kidney PTH/PTHrP receptors indicate that they do not fit comfortably into either of  
10 these G-protein linked receptor subfamilies. Overall homology of the rat and human PTH/PTHrP receptors with the glycopeptide receptor and adrenergic/muscarinic subfamilies is approximately 10 to 20%, with a somewhat higher degree of homology within the transmembrane  
15 domains. The latter is to be expected because of the limited menu of hydrophobic amino acids that could occur in those regions. Twenty percent homology is far less than that found among the receptors generally accepted to be members of each of these subfamilies. Additionally,  
20 there are no portions of these sequences that have what could be characterized as intense homology (i.e., exactly matching amino acid sequences), even over limited regions.

Recent comparison with the newly characterized  
25 secretin and calcitonin receptors (Ishihara et al., EMBO J 10:1635, 1991; Lin et al., Science 254:1022, 1991) has revealed between 30 and 40% identity between these receptors and the PTH/PTHrP receptor. Although the PTH/PTHrP receptor is more than 100 amino acids longer  
30 than the calcitonin receptor, there is an ~32% identify between the amino acid sequences of the opossum kidney PTH/PTHrP receptor (SEQ ID NO NO.:2) and porcine kidney calcitonin receptor (GenBank accession no. M74420). A stretch of 17 out of 18 amino acids in the putative  
35 transmembrane domain VII are identical. Also, two out of

- 34 -

four N-linked glycosylation sites and the position of seven out of eight potentially extracellular cysteines are conserved. Major differences between the two receptors appear to lie in their NH<sub>2</sub>-terminal and COOH-terminal domains. Comparison of amino acid sequences of the rat secretin receptor (GenBank accession no. X59132) and the human PTH/PTHrP receptor indicates that there is a 43% identity between these two receptors, with a stretch of 21 out of 25 amino acids of the putative transmembrane domain VII being identical. The similarity between the PTH/PTHrP, calcitonin and secretin receptors suggests that they represent a new family of seven transmembrane-spanning G protein-coupled receptors that activate adenylate cyclase. Given the amino acid sequences of these receptors, those skilled in the art would be able to compare these sequences for regions of identity which would be useful in the design of nucleic acid probes which could then be used for the identification and isolation of other receptors which would belong to this family.

#### Deposit of Clones

Under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure, the cDNA expression plasmids R15B, OK-O, and OK-H; the phage HPG1; and a plasmid (termed 8A6) containing part of the human clone have been deposited with the American Type Culture Collection (ATCC), where they bear the respective accession numbers ATCC No. 68571, 68572, 68573, 40998 and 68570. Applicants' assignee, The General Hospital Corporation, represents that the ATCC is a depository affording permanence of the deposits and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the

- 35 -

public of the material so deposited will be irrevocably removed upon the granting of a patent. The material will be available during the pendency of the patent application to one determined by the Commissioner to be  
5 entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited  
10 plasmid, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer. Applicants' assignee acknowledges its responsibility to replace the deposits should the  
15 depository be unable to furnish a sample when requested due to the condition of the deposit.

#### POLYPEPTIDES

Polypeptides according to the invention include the opossum and rat and human parathyroid hormone  
20 receptors as shown in Figs. 1-3 and 6, respectively, and any other naturally-occurring receptor which can be produced by methods analogous to those used to clone and express these receptors, or by methods utilizing as a probe all or part of one of the sequences described  
25 herein. In addition, any analog or fragment of a PTH receptor capable of binding to a parathyroid hormone or a parathyroid hormone-related protein is within the invention.

Specific receptor analogs of interest include  
30 full-length or partial receptor proteins having an amino acid sequence which differs only by conservative amino acid substitutions: for example, substitution of one amino acid for another of the same class (e.g., valine for glycine; arginine for lysine, etc.), or by one or  
35 more non-conservative amino-acid substitutions,

- 36 -

deletions, or insertions located at positions which do not destroy the receptor's ability to bind to parathyroid hormone or parathyroid hormone-related protein.

- Specific receptor fragments of particular interest
- 5 include, but are not limited to, portions of the receptor deduced to be extracellular from the primary amino acid sequence, using a hydrophobicity/hydrophilicity calculation such as the Chou-Fasman method (see, e.g., Chou and Fasman, Ann. Rev. Biochem. 47:251, 1978).
- 10 Hydrophilic domains, particularly ones surrounded by hydrophobic stretches (e.g., transmembrane domains) of at least 10 amino acids, present themselves as strong candidates for extracellular domains. Fig. 21 illustrates a predicted arrangement of extracellular,
- 15 intracellular, and transmembrane domains of one PTH receptor.

- Examples of specific PTH receptor fragments include those with the following amino acid sequences (shown as standard single-letter symbols), derived from
- 20 the deduced amino acid sequence of the R15B clone:
- Extracellular domains:

- RP-1: TNETREREVFDR LGMIYTVG (SEQ ID NO.: 5)
- RP-2: VLYSGFTLDEAERL TEEEL (SEQ ID NO.: 6)
- RP-3: VTFFLYFLATNYYWILVEG (SEQ ID NO.: 7)
- 25 RP-4: Y-RATLANTGCWDLSSGHKKWIIQVP (SEQ ID NO.: 8)
- RP-5: PYTEVSGTLWQIQMHYEM (SEQ ID NO.: 9)
- RP-6: DDVFTKEEQIFLLHRAQA (SEQ ID NO.: 10)

Intracellular domains:

- RPI-7: FRRLHCTRNY (SEQ ID NO.: 11)
- 30 RPI-8: EKKYLGWFTL (SEQ ID NO.: 12)
- RPI-9: VLATKLRETNAGRC DTRQQYRKLLK (SEQ ID NO.: 13)

These fragments were synthesized and purified by HPLC according to the method of Keutmann et al., (Endocrinology 117: 1230, 1984).

- 37 -

EXPRESSION OF POLYPEPTIDES

Polypeptides according to the invention may be produced by expression from a recombinant nucleic acid having a sequence encoding part or all of a cell receptor of the invention, using any appropriate expression system: e.g., transformation of a suitable host cell (either prokaryotic or eukaryotic) with the recombinant nucleic acid in a suitable expression vehicle (e.g., pcdNAI). The precise host cell used is not critical to the invention; however, in the case wherein the polypeptides of the invention include all or part of the PTH/PTHrP receptor, the following host cells are preferred: COS cells, LLC-PK1 cells, OK cells, AtT20 cells, and CHO cells. The method of transfection and the choice of expression vehicle will depend on the host system selected. Mammalian cell transfection methods are described, e.g., in Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989); expression vehicles may be chosen from those discussed, e.g., in Cloning Vectors: A Laboratory Manual (P.H. Pouwels et al., 1985, Supp. 1987). Stably transfected cells are produced via integration of receptor DNA into the host cell chromosomes. Suitable DNAs are inserted into pcdNA, pcdNAI-Neo, or another suitable plasmid, and then cells are transfected with this plasmid with or without cotransfection with psV-2-Neo, or psV-2-DHFR by standard electroporation, calcium phosphate, and/or DEAE/Dextran techniques. Selection of transfected cells is performed using progressively increasing levels of G418 (Geneticin, GIBCO), and if necessary, methotrexate.

DNA sequences encoding the polypeptides of the invention can also be expressed in a prokaryotic host cell. DNA encoding a cell receptor or receptor fragment is carried on a vector operably linked to control signals capable of effecting expression in the prokaryotic host.

- 38 -

If desired, the coding sequence may contain, at its 5' end, a sequence encoding any of the known signal sequences capable of effecting secretion of the expressed protein into the periplasmic space of the host cell, thereby facilitating recovery of the protein and subsequent purification. Prokaryotes most frequently used are various strains of E. coli; however, other microbial strains may also be used. Plasmid vectors are used which contain replication origins, selectable markers, and control sequences derived from a species compatible with the microbial host. For example, E. coli may be transformed using derivatives of pBR322, a plasmid constructed by Bolivar et al. (Gene 2: 95, 1977) using fragments derived from three naturally-occurring plasmids, two isolated from species of Salmonella, and one isolated from E. coli. pBR322 contains genes from ampicillin and tetracycline resistance, and thus provides multiple selectable markers which can be either retained or destroyed in constructing the desired expression vector. Commonly used prokaryotic control sequences (also referred to as "regulatory elements") are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences. Promoters commonly used to direct protein expression include the beta-lactamase (penicillinase), the lactose (lac) (Chang et al., Nature 198: 1056, 1977) and the tryptophan (Trp) promoter systems (Goeddel et al., Nucl. Acids Res. 8: 4057, 1980) as well as the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Simatake et al., Nature 292:128, 1981).

The nature of the cell receptor proteins of the invention is such that, upon expression within a cell, it is moved to the cellular membrane and partially through the membrane, so that part of it remains embedded in the

- 39 -

membrane, part extends outside the cell, and part remains within the cell. Transformed cells bearing such embedded cell receptors may themselves be employed in the methods of the invention, or the receptor protein may be  
5 extracted from the membranes and purified.

Expression of peptide fragments lacking the hydrophobic portions of the protein responsible for anchoring the intact protein in the cellular membrane would not be expected to become embedded in the membrane;  
10 whether they remain within the cell or are secreted into the extracellular medium depends upon whether or not a mechanism promoting secretion (e.g., a signal peptide) is included. If secreted, the polypeptide of the invention can be harvested from the medium; if not, the cells must  
15 be broken open and the desired polypeptide isolated from the entire contents of the cells. Specific examples of polypeptides which might be expressed include, without limitation:

1) Amino-terminal portion comprising amino acids  
20 1-192, including the putative leader sequence, of the rat bone PTH/PTHrP receptor as shown in Fig. 3.

2) Amino-terminal portion comprising amino acids 27-192, excluding the putative leader sequence, of the rat bone PTH/PTHrP receptor as shown in Fig. 3.

25 3) The full-length PTH/PTHrP receptor from rat bone, as shown in Fig 3.

4) RP-1 (as described above).

5) RP-2 (as described above).

The polypeptide of the invention can be readily  
30 purified using affinity chromatography. Antibodies to these polypeptides, or the receptor specific ligands, (e.g., the hormones PTH and PTHrP for the PTH/PTHrP receptor) may be covalently coupled to a solid phase support such as Sepharose 4 CNBr-activated sepharose  
35 (Pharmacia), and used to separate the polypeptide of the

- 40 -

invention from any contaminating substances. Typically 1 mg of ligand or antibody will be incubated with CNBr-activated sepharose at 4°C for 17-20 h (with shaking). The sepharose is rinsed with 1 M Tris HCL (pH8) to block  
5 excess active sites. The sepharose-PTH, sepharose-PTHrP, or sepharose-antibody is then incubated with the crude polypeptide in phosphate-buffered saline (pH 7.4) at 4°C for 2 h (with shaking). The sepharose is then typically packed in a column, thoroughly washed with PBS (typically  
10 10 times the column volume), and eluted with dilute HCL in H<sub>2</sub>O (pH 1.85). The eluate may then be concentrated by lyophilization and its purity checked, for example, by reverse phase HPLC.

#### ANTI-CELL RECEPTOR ANTIBODIES

15 Cell receptor or receptor fragments of the invention may be used to generate antibodies by any conventional method well known to those skilled in the art, including those which generate polyclonal antibodies and those which generate monoclonal antibodies. For  
20 example, the deduced amino acid sequence of the PTH receptor reveals a protein structure that appears to have several transmembrane (i.e., hydrophobic) domains interspersed with presumably extracellular and intracellular regions (see Fig. 21) analogous to those  
25 found in other G protein-linked receptors. This information can be used to guide the selection of regions of the receptor protein which would be likely to be exposed on the cell surface, and thus would be presented to antibodies in vivo. A short peptide representing one  
30 or more of such regions may be synthesized (e.g., chemically or by recombinant DNA techniques) and used to immunize an animal (e.g., a rabbit or a mouse) to generate polyclonal or monoclonal antibodies. For example, certain of the peptides of the PTH/PTHrP  
35 receptor listed above (RP-1, RP-5 and RP-6) have been

- 41 -

chemically synthesized using standard techniques and used to generate polyclonal antibodies in rabbits by the following procedure:

A preparation of a given peptide emulsified with complete Freund's Adjuvant is injected intradermally into rabbits. Booster injections are emulsified in or complete adjuvant and injected at monthly intervals.

Antibody titer is assessed using either of two methods. First, serial dilutions of the antiserum in 1% normal rabbit serum are incubated with  $^{125}\text{I}$ -labelled PTH/PTHrP receptor fragment by standard methods (e.g., see Segre et al., supra) for 24 h at 4° C. The bound  $^{125}\text{I}$ -PTH/PTHrP receptor fragments are separated from unbound by addition of 100  $\mu\text{l}$  of second antibody (anti-rabbit IgG, Sigma) diluted 1:20 and 1 ml of 5% polyethylene glycol, followed by centrifugation at 2000 rpm for 30 min. at 4° C. The supernatant is removed and the pellet analyzed for radioactivity in a  $\gamma$ -counter. In the second method, cell lines expressing either native (e.g., ROS 17/2.8, OK, SaOS-02 cells) or recombinant (COS cells or CHO cells transfected with R15B, OK-O or OK-H) PTH/PTHrP receptors are incubated with serially diluted antibody at 4°C, 20°C or 37°C for 1- 4 h. The cells are rinsed with PBS (x3) and incubated for 2 h at 4°C with  $^{125}\text{I}$ -labelled (NEN, Dupont) or FITC-labelled (Sigma) second antibodies. After rinsing (x3 with PBS), the cells were either lysed with 0.1 M NaOH and counted in  $\gamma$ -counter (if  $^{125}\text{I}$ -labelled second antibody was used) or fixed with 1% paraformaldehyde and examined by fluorescent microscopy (if FITC-labelled second antibody was used).

Another method for producing antibodies utilizes as antigen the intact cell receptor protein of the invention expressed on the surface of cells (e.g., mammalian cells, such as COS cells, transfected with DNA

- 42 -

encoding the receptor). Such cells are prepared by standard techniques, e.g., by the DEAE-dextran transfection method, using a vector encoding and capable of directing high-level expression of the cell receptor.

- 5 Such cells may be used to generate polyclonal or monoclonal antibodies. For example, monoclonal antibodies specific for the PTH/PTHrP receptor may be produced by the following procedure:

- Intact COS cells expressing high levels of rat recombinant PTH receptors on the cell surface are injected intraperitoneally (IP) into Balb-c mice (Charles River Laboratories, Willmington, MA). The mice are boosted every 4 weeks by IP injection, and are hyperimmunized by an intravenous (IV) booster 3 days before fusion. Spleen cells from the mice are isolated and are fused by standard methods to myeloma cells. Hybridomas are selected in standard hypoxanthine/aminopterin/thymine (HAT) medium, according to standard methods. Hybridomas secreting antibodies which recognize the PTH receptor are initially identified by screening with cell lines which naturally express abundant copies of the PTH-receptor per cell (such as ROS17/2.8 or OK cells), using standard immunological techniques. Those hybridomas which produce antibodies capable of binding to the PTH receptor are cultured and subcloned. Secondary screening with radioreceptor and CAMP stimulation assays can then be performed to further characterize the monoclonal antibodies (see below).

#### SCREENING FOR PTH RECEPTOR ANTAGONISTS AND AGONISTS

- 30 The polypeptides and antibodies of the invention and other compounds may be screened for PTH-competition and for antagonistic or agonistic properties using the assays described herein.

- In one example, those antibodies that recognize the PTH receptor on the intact cells are screened for
- 35

- 43 -

their ability to compete with PTH or PTHrP for binding to a PTH/PTHrP receptor. Cells expressing PTH receptor on the cell surface are incubated with the  $^{125}\text{I}$ -PTH analog,  $^{125}\text{I}$ -NlePTH or  $^{125}\text{I}$ -PTHrP in the presence or absence of  
5 the polyclonal or monoclonal antibody to be tested, for 4 h at 15°C. The antibody used may be from crude antiserum, cell medium, or ascites, or in purified form. After incubation, the cells are rinsed with binding buffer (e.g., physiological saline), lysed, and  
10 quantitatively analyzed for radioactivity using a gamma-counter. Antibodies that reduce binding of the PTH analog to the PTH receptor are classified as competitive; those which do not are noncompetitive.

Compounds, including antibodies and polypeptides,  
15 may be screened for their agonistic or antagonistic properties using the cAMP accumulation, intracellular calcium, and/or inositol phosphate assays described above. Cells expressing PTH receptor on the cell surface are incubated with PTH, PTH-receptor antibody, or a  
20 combination of both, for 5 - 60 minutes at 37°C, in the presence of 2 mM IBMX (3-isobutyl-1-methyl-xanthine, Sigma, St. Louis, MO). Cyclic AMP accumulation is measured by specific radio-immunoassay, as described above. A compound that competes with PTH for binding to  
25 the PTH receptor, and that inhibits the effect of PTH on cAMP accumulation, is considered a competitive PTH antagonist. Conversely, a compound that does not compete for PTH binding to the PTH receptor, but which still prevents PTH activation of cAMP accumulation (presumably  
30 by blocking the receptor activation site) is considered a non-competitive antagonist. A compound that competes with PTH for binding to the PTH receptor, and which stimulates cAMP accumulation in the presence or absence of PTH, is a competitive agonist. A compound that does  
35 not compete with PTH for binding to the PTH receptor but

- 44 -

which is still capable of stimulating cAMP accumulation in the presence or absence of PTH, or which stimulates a higher accumulation than that observed by PTH alone, would be considered a non-competitive agonist.

5 USE

The polypeptides, antibodies, and other compounds of the invention are useful for the diagnosis, classification, prognosis, and/or treatment of disorders which may be characterized as related to the interaction  
10 between a cell receptor of the invention and its specific ligand. For example, some forms of hypercalcemia and hypocalcemia are related to the interaction between PTH and PTHrP and the PTH/PTHrP receptor(s). Hypercalcemia is an condition in which there is an abnormal elevation  
15 in serum calcium level; it is often associated with other diseases, including hyperparathyroidism, osteoporosis, carcinomas of the breast, lung and prostate, epidermoid cancers of the head and neck of the esophagus, multiple myeloma, and hypernephroma. Hypocalcemia, a condition in  
20 which the serum calcium level is abnormally low, may result from a deficiency of effective PTH, e.g., following thyroid surgery.

In a first example, the compounds of the invention are used to manufacture diagnostic agents which are used  
25 as diagnostic tools to diagnose hypercalcemia and to distinguish between hypercalcemic conditions, i.e., to differentiate hypercalcemia mediated by PTH or PTHrP (e.g., hyperparathyroidism and humoral hypercalcemia of malignancy), from hypercalcemia associated with diseases  
30 which do not involve these factors (e.g., local osteolytic hypercalcemia mediated by the presence of metastatic tumor cells in direct contact with bone, and certain rare types of malignancy-related hypercalcemias mediated by an increase of humoral factors, such as  
35 osteoclast activating factor (interleukin), lymphotoxin,

- 45 -

calcitriol, type E prostaglandins, and vitamin D-like sterols).

In one method of diagnosis, serum total and/or ionized calcium levels are measured by standard techniques before and after the administration of the PTH or PTHrP antagonists of the invention. PTH or PTHrP related hypercalcemias would be detectable as a decrease in serum calcium levels following administration of the antagonist of the invention. In contrast, for hypercalcemic conditions mediated by factors other than PTH or PTHrP, the serum calcium levels would remain unchanged even after administration of the antagonist.

Another diagnostic application of the invention permits measurement of the level of PTH or PTHrP in a biological sample in order to diagnose PTH or PTHrP related tumors, e.g., tumors which are associated with humoral hypercalcemia of malignancy, and for monitoring the levels of PTH or PTHrP during cancer therapy. This method involves assaying binding of the recombinant parathyroid hormone receptor of the invention to PTH or PTHrP present in a tissue sample, using the binding assay described herein. The level of binding may be determined directly (e.g., by using radioactively labelled PTH receptor, and assaying the radioactivity bound to endogenous PTH). Alternatively, binding of PTH receptor to the sample (e.g., a tissue section) may be followed by staining of the tissue sections with an antibody specific for the PTH receptor, using standard immunological techniques (Chin et al., Hybridoma 5:339, 1986).

In a third diagnostic approach, one could stably transfect cell lines (by the methods described in Ausubel et al., Current Protocols in Molecular Biology, Wiley Publishers, New York, 1987) with a PTH receptor gene linked to an appropriate promoter (e.g., the metallothionine promoter). Alternatively, the PTH/PTHrP

- 46 -

receptor could be expressed from a eukaryotic vector, i.e., pCDNAI, and cotransfected with a mutant DHFR gene that will allow further gene amplification via methotrexate selection (Simonsen et al., Proc. Natl. Acad. Sci., 80:2495-2499, 1983). Such high-level expression of the gene produces an immortal cell line which is oversensitive to PTH or PTHrP. Such cells provide a particularly useful tool for detecting serum blood levels of PTH or PTHrP. Such a cell line may be used for diagnosis of conditions involving elevated PTH or PTHrP levels (e.g., those described above) or for conditions involving unusually low levels of PTH or PTHrP (e.g., those described above). Such a cell line is also useful for monitoring the regression or increase of PTH or PTHrP levels during therapy for hypercalcemia or hypocalcemia, respectively.

A patient who is suspected of being hypercalcemic may be treated using the compounds of the invention. Rapid intervention is important because symptoms may appear abruptly and, unless reversed, can be fatal. In one application, serum calcium levels are stabilized by an immediate course of treatment which includes antagonists of PTH or PTHrP. Such antagonists include the compounds of the invention which have been determined (by the assays described herein) to interfere with PTH receptor-mediated cell activation. To administer the antagonist, the appropriate antibody or peptide (is used in the manufacture of a medicament, generally by being formulated in an appropriate carrier such as physiological saline, and administered intravenously, at a dosage that provides adequate competition for PTH or PTHrP binding to the PTH receptor (e.g., a dosage sufficient to lower the serum calcium level to below 10 mg/dl). Typical dosage would be 1 ng to 10 mg of the antibody or peptide per kg body weight per day.

- 47 -

Treatment may be repeated as necessary for long term maintenance of acceptable calcium levels (i.e., levels < 10.1 mg/dl). This may be necessary for acute treatment of an underlying disease condition triggering

- 5 hypercalcemia; or it may be used, e.g., for chronic treatment of conditions such as osteoporosis.

- In another application, the compounds of the invention which have been characterized, according to the methods of the invention, to be agonists are used
- 10 therapeutically to treat hypocalcemia: e.g., that resulting from the partial or complete surgical removal of the parathyroid glands. Agonists may be formulated in a suitable carrier (e.g., physiological saline) and are preferably administered intravenously in a dosage that
- 15 causes a rise in serum calcium to an acceptable level (i.e., approximately 8 mg/dl). A useful dosage range would be 1 ng to 10 mg of the agonist per kg body weight per day. Treatment may be repeated as necessary to maintain suitable serum calcium levels; long term
- 20 treatment may be necessary for patients who have undergone parathyroid gland removal.

- The nucleic acids of the invention may also be used therapeutically. Oligonucleotides which are antisense to PTH receptor mRNA (or nucleic acid
- 25 constructs which express RNA that is antisense to PTH receptor mRNA) may be utilized as an anticancer therapy. This approach is useful, e.g., for hypercalcemias resulting from a genomic rearrangement or amplification which increases the amount or activity of PTH receptor,
- 30 PTH or PTHrP. The method would involve introduction of the antisense oligonucleotide into the tumor cells in vivo. The antisense strand hybridizes with endogenous PTH receptor mRNA, interfering with translation of the protein, thereby reducing production of PTH receptor in
- 35 such cells, and reducing PTH/PTHrP-associated neoplastic

- 48 -

growth. Methods for antisense design and introduction into host cells are described, for example, in Weinberg et al., U.S. Patent No. 4,740,463, herein incorporated by reference. The biochemical characterization of the OK-H, OK-O and R15B PTH/PTHrP receptors of the invention demonstrate that the two transduction pathways now known to be triggered by the interaction of PTH with its receptor are distinct and may be separated. The predicted amino acid sequences of these receptors indicate that OK-H, which does not appear to activate inositol phosphate metabolism to any detectable degree, is 70 amino acids shorter at the carboxy-terminus than OK-O or R15B. By using the sequences of the invention and the information disclosed herein, one could clone and then alter (e.g. by site-directed mutagenesis) PTH/PTHrP receptor genes from any species to generate PTH/PTHrP receptors which do not activate phospholipase C. This could potentially allow the separation of different PTH-mediated actions, including bone resorption and bone formation, and could of great importance for the treatment of various bone disorders such as osteoporosis.

Nucleic acids of the invention which encode a PTH receptor may also be linked to a selected tissue-specific promoter and/or enhancer and the resultant hybrid gene introduced, by standard methods (e.g., as described by Leder et al., U.S. Patent No. 4,736,866, herein incorporated by reference), into an animal embryo at an early developmental stage (e.g., the fertilized oocyte stage), to produce a transgenic animal which expresses elevated levels of PTH receptor in selected tissues (e.g., the osteocalcin promoter for bone). Such promoters are used to direct tissue-specific expression of the PTH receptor in the transgenic animal. The form of PTH receptor utilized can be one which encodes a PTH receptor similar to that of the animal species used, or

- 49 -

it can encode the PTH receptor homolog of a different species. In one particular example, transgenic chickens are engineered to express the PTH receptor from a promoter which directs high-level expression in chicken  
5 oviducts. Such an animal is expected to produce eggs with higher calcium content, and thus harder shells.

Other Embodiments

Other embodiments are within the following claims. For example, the nucleic acid of the invention includes  
10 genes or cDNAs or RNAs originally isolated from any vertebrate species, including birds or mammals such as marsupials, rodents, or humans. The high degree of homology demonstrated for the PTH receptors from such diverse species as opossum, rat, and human indicates that  
15 the methods of isolating PTH receptors disclosed herein will be broadly applicable to the isolation of related cell receptors from a wide variety of species.

- 50 -

COMPUTER SUBMISSION OF DNA AND AMINO ACID SEQUENCES

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Segre, Gino V.  
Kronenberg, Henry M.  
Abou-Samra, Abdul-Badi  
Juppner, Harald  
Potts, John T., Jr.  
Schipani, Ernestina
- (ii) TITLE OF INVENTION: PARATHYROID HORMONE RECEPTOR AND DNA  
ENCODING SAME
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Fish & Richardson  
(B) STREET: 225 Franklin Street  
(C) CITY: Boston  
(D) STATE: Massachusetts  
(E) COUNTRY: U.S.A.  
(F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage  
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX  
(C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)  
(D) SOFTWARE: WordPerfect (Version 5.0)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 07/681,702  
(B) FILING DATE: April 5, 1991
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Paul T. Clark  
(B) REGISTRATION NUMBER: 30,162  
(C) REFERENCE/DOCKET NUMBER: 00786/071001
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (617) 542-5070  
(B) TELEFAX: (617) 542-8906

- 51 -

(C) TELEX:

200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:1862
- (B) TYPE:nucleic acid
- (C) STRANDEDNESS:double
- (D) TOPOLOGY:linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 1:

TGGGCACAGC CACCCTGTTG GTAGTCCAGG GGCCAGCCCA CTGAGCTGGC ATATCAGCTG	60
GTGGCCCCGT TGGACTCGGC CCTAGGGAAC GCGGCG ATG GGA GCG CCC CGG ATC	115
Met Gly Ala Pro Arg Ile	
1 5	
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC	163
Ser His Ser Leu Ala Leu Leu Cys Cys Ser Val Leu Ser Ser Val	
10 15 20	
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC	211
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile	
25 30 35	
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG	259
Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu	
40 45 50	
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA	307
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser	
55 60 65 70	
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC	355
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro	
75 80 85	
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT	403
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp	
90 95 100	
GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA	451
Gly Phe Cys Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Ala Gly	
105 110 115	
GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC	499
Val Pro Gly Lys Val Val Ala Val Pro Cys Pro Asp Tyr Phe Tyr Asp	
120 125 130	
TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC	547
Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser	
135 140 145 150	

- 52 -

TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA	595
Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu	
155 160 165	
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT	643
Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp	
170 175 180	
CGC CTC GGA ATG ATC TAC ACT GTG GGC TAC TCC ATC TCT CTG GGC TCC	691
Arg Leu Gly Met Ile Tyr Thr Val Gly Tyr Ser Ile Ser Leu Gly Ser	
185 190 195	
CTC ACT GTG GCT GTG CTG ATT CTG GGT TAC TTT AGG AGG TTA CAT TGC	739
Leu Thr Val Ala Val Leu Ile Leu Gly Tyr Phe Arg Arg Leu His Cys	
200 205 210	
ACC CGA AAC TAC ATT CAC ATG CAT CTC TTC GTG TCC TTT ATG CTC CGG	787
Thr Arg Asn Tyr Ile His Met His Leu Phe Val Ser Phe Met Leu Arg	
215 220 225 230	
GCT GTA AGC ATC TTC ATC AAG GAT GCT GTG CTC TAC TCG GGG GTT TCC	835
Ala Val Ser Ile Phe Ile Lys Asp Ala Val Leu Tyr Ser Gly Val Ser	
235 240 245	
ACA GAT GAA ATC GAG CGC ATC ACC GAG GAG GAG CTG AGG GCC TTC ACA	883
Thr Asp Glu Ile Glu Arg Ile Thr Glu Glu Glu Leu Arg Ala Phe Thr	
250 255 260	
GAG CCT CCC CCT GCT GAC AAG GCG GGT TTT GTG GGC TGC AGA GTG GCG	931
Glu Pro Pro Pro Ala Asp Lys Ala Gly Phe Val Gly Cys Arg Val Ala	
265 270 275	
GTA ACC GTC TTC CTT TAC TTC CTG ACC ACC AAC TAC TAC TGG ATC CTG	979
Val Thr Val Phe Leu Tyr Phe Leu Thr Thr Asn Tyr Tyr Trp Ile Leu	
280 285 290	
GTG GAA GGC CTC TAC CTT CAC AGC CTC ATC TTC ATG GCT TTT TTC TCT	1027
Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser	
295 300 305 310	
GAG AAA AAG TAT CTC TGG GGT TTC ACA TTA TTT GGC TGG GGC CTC CCT	1075
Glu Lys Lys Tyr Leu Trp Gly Phe Thr Leu Phe Gly Trp Gly Leu Pro	
315 320 325	
GCC GTG TTT GTC GCT GTG TGG GTG ACC GTG AGG GCT ACA CTG GCC AAC	1123
Ala Val Phe Val Ala Val Trp Val Thr Val Arg Ala Thr Leu Ala Asn	
330 335 340	
ACT GAG TGC TGG GAC CTG AGT TCG GGG AAT AAG AAA TGG ATC ATA CAG	1171
Thr Glu Cys Trp Asp Leu Ser Ser Gly Asn Lys Lys Trp Ile Ile Gln	
345 350 355	

- 53 -

GTG CCC ATC CTG GCA GCT ATT GTG GTG AAC TTT ATT CTT TTT ATC AAT	1219
Val Pro Ile Leu Ala Ala Ile Val Val Asn Phe Ile Leu Phe Ile Asn	
360 365 370	
ATA ATC AGA GTC CTG GCT ACT AAA CTC CGG GAG ACC AAT GCA GGG AGA	1267
Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg	
375 380 385 390	
TGT GAC ACG AGG CAA CAG TAT AGA AAG CTG CTG AAG TCC ACG CTA GTC	1315
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Lys Ser Thr Leu Val	
395 400 405	
CTC ATG CCG CTA TTT GGG GTG CAC TAC ATC GTC TTC ATG GCC ACG CCG	1363
Leu Met Pro Leu Phe Gly Val His Tyr Ile Val Phe Met Ala Thr Pro	
410 415 420	
TAC ACA GAA GTA TCA GGG ATT CTT TGG CAA GTC CAA ATG CAC TAT GAA	1411
Tyr Thr Glu Val Ser Gly Ile Leu Trp Gln Val Gln Met His Tyr Glu	
425 430 435	
ATG CTC TTC AAT TCA TTC CAG GGA TTT TTC GTT GCC ATT ATA TAC TGT	1459
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
440 445 450	
TTC TGC AAT GGA GAG GTA CAA GCA GAG ATC AAG AAG TCA TGG AGC CGA	1507
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Lys Lys Ser Trp Ser Arg	
455 460 465 470	
TGG ACC CTG GCC TTG GAC TTC AAG CGG AAG GCC CGG AGT GGC AGC AGT	1555
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
475 480 485	
ACC TAC AGC TAT GGC CCC ATG GTG TCA CAT ACA AGT GTC ACC AAT GTG	1603
Thr Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
490 495 500	
GGA CCT CGA GGG GGC TGG CCT TGT CCC TCA GCC CTC GAC TAGCTCCTGG	1652
Gly Pro Arg Gly Gly Trp Pro Cys Pro Ser Ala Leu Asp	
505 510 515	
GGCTGGAGCC AGTGCCAATG GCCATCACCA GTGCCTGGC TATGTGAAGC ATGGTTCCAT	1712
TTCTGAGAAC TCATTGCCTT CATCTGGCCC AGAGCCTGGC ACCAAAGATG ACGGGTATCT	1772
CAATGGCTCT GGACTTTATG AGCCAATGGT TGGGGAACAG CCCCCTCCAC TCCTGGAGGA	1832
GGAGAGAGAG ACAGTCATGT GACCCATATC	1862

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1863  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 2:

TTGGGCACAGC CACCCTGTTG GTAGTCCAGG GGCCAGCCCA CTGAGCTGGC ATATCAGCTG	60
GTGGCCCCGT TGGACTCGGC CCTAGGGAAC GGCGGCG ATG GGA GCG CCC CGG ATC	115
Met Gly Ala Pro Arg Ile	
1 5	
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC	163
Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val	
10 15 20	
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC	211
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile	
25 30 35	
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG	259
Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu	
40 45 50	
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA	307
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser	
55 60 65 70	
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC	355
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro	
75 80 85	
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT	403
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp	
90 95 100	
GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA	451
Gly Phe Cys Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Ala Gly	
105 110 115	
GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC	499
Val Pro Gly Lys Val Val Ala Val Pro Cys Pro Asp Tyr Phe Tyr Asp	
120 125 130	

- 55 -

TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser 135 140 145 150	547
TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu 155 160 165	595
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp 170 175 180	643
CGC CTC GGA ATG ATC TAC ACT GTG GGC TAC TCC ATC TCT CTG GGC TCC Arg Leu Gly Met Ile Tyr Thr Val Gly Tyr Ser Ile Ser Leu Gly Ser 185 190 195	691
CTC ACT GTG GCT GTG CTG ATT CTG GGT TAC TTT AGG AGG TTA CAT TGC Leu Thr Val Ala Val Leu Ile Leu Gly Tyr Phe Arg Arg Leu His Cys 200 205 210	739
ACC CGA AAC TAC ATT CAC ATG CAT CTC TTC GTG TCC TTT ATG CTC CGG Thr Arg Asn Tyr Ile His Met His Leu Phe Val Ser Phe Met Leu Arg 215 220 225 230	787
GCT GTA AGC ATC TTC ATC AAG GAT GCT GTG CTC TAC TCG GGG GTT TCC Ala Val Ser Ile Phe Ile Lys Asp Ala Val Leu Tyr Ser Gly Val Ser 235 240 245	835
ACA GAT GAA ATC GAG CGC ATC ACC GAG GAG GAG CTG AGG GCC TTC ACA Thr Asp Glu Ile Glu Arg Ile Thr Glu Glu Glu Leu Arg Ala Phe Thr 250 255 260	883
GAG CCT CCC CCT GCT GAC AAG GCG GGT TTT GTG GGC TGC AGA GTG GCG Glu Pro Pro Pro Ala Asp Lys Ala Gly Phe Val Gly Cys Arg Val Ala 265 270 275	931
GTA ACC GTC TTC CTT TAC TTC CTG ACC ACC AAC TAC TAC TGG ATC CTG Val Thr Val Phe Leu Tyr Phe Leu Thr Thr Asn Tyr Tyr Trp Ile Leu 280 285 290	979
GTG GAA GGC CTC TAC CTT CAC AGC CTC ATC TTC ATG GCT TTT TTC TCT Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser 295 300 305 310	1027
GAG AAA AAG TAT CTC TGG GGT TTC ACA TTA TTT GGC TGG GGC CTC CCT Glu Lys Lys Tyr Leu Trp Gly Phe Thr Leu Phe Gly Trp Gly Leu Pro 315 320 325	1075
GCC GTG TTT GTC GCT GTG TGG GTG ACC GTG AGG GCT ACA CTG GCC AAC Ala Val Phe Val Ala Val Trp Val Thr Val Arg Ala Thr Leu Ala Asn 330 335 340	1123

- 56 -

ACT GAG TGC TGG GAC CTG AGT TCG GGG AAT AAG AAA TGG ATC ATA CAG 1171  
 Thr Glu Cys Trp Asp Leu Ser Ser Gly Asn Lys Lys Trp Ile Ile Gln  
 345 350 355

GTG CCC ATC CTG GCA GCT ATT GTG GTG AAC TTT ATT CTT TTT ATC AAT 1219  
 Val Pro Ile Leu Ala Ala Ile Val Val Asn Phe Ile Leu Phe Ile Asn  
 360 365 370

ATA ATC AGA GTC CTG GCT ACT AAA CTC CGG GAG ACC AAT GCA GGG AGA 1267  
 Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg  
 375 380 385 390

TGT GAC ACG AGG CAA CAG TAT AGA AAG CTG CTG AAG TCC ACG CTA GTC 1315  
 Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Lys Ser Thr Leu Val  
 395 400 405

CTC ATG CCG CTA TTT GGG GTG CAC TAC ATC GTC TTC ATG GCC ACG CCG 1363  
 Leu Met Pro Leu Phe Gly Val His Tyr Ile Val Phe Met Ala Thr Pro  
 410 415 420

TAC ACA GAA GTA TCA GGG ATT CTT TGG CAA GTC CAA ATG CAC TAT GAA 1411  
 Tyr Thr Glu Val Ser Gly Ile Leu Trp Gln Val Gln Met His Tyr Glu  
 425 430 435

ATG CTC TTC AAT TCA TTC CAG GGA TTT TTC GTT GCC ATT ATA TAC TGT 1459  
 Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys  
 440 445 450

TTC TGC AAT GGA GAG GTA CAA GCA GAG ATC AAG AAG TCA TGG AGC CGA 1507  
 Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Lys Lys Ser Trp Ser Arg  
 455 460 465 470

TGG ACC CTG GCC TTG GAC TTC AAG CCG AAG GCC CGG AGT GGC AGC AGT 1555  
 Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser  
 475 480 485

ACC TAC AGC TAT GGC CCC ATG GTG TCA CAT ACA AGT GTC ACC AAT GTG 1603  
 Thr Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val  
 490 495 500

GGA CCT CGA GGG GGG CTG GCC TTG TCC CTC AGC CCT CGA CTA GCT CCT 1651  
 Gly Pro Arg Gly Gly Leu Ala Leu Ser Leu Ser Pro Arg Leu Ala Pro  
 505 510 515

GGG GCT GGA GCC AGT GCC AAT GGC CAT CAC CAG TTG CCT GGC TAT GTG 1699  
 Gly Ala Gly Ala Ser Ala Asn Gly His His Gln Leu Pro Gly Tyr Val  
 520 525 530

AAG CAT GGT TCC ATT TCT GAG AAC TCA TTG CCT TCA TCT GGC CCA GAG 1747  
 Lys His Gly Ser Ile Ser Glu Asn Ser Leu Pro Ser Ser Gly Pro Glu  
 535 540 545 550

- 57 -

CCT GGC ACC AAA GAT GAC GGG TAT CTC AAT GGC TCT GGA CTT TAT GAG 1795  
 Pro Gly Thr Lys Asp Asp Gly Tyr Leu Asn Gly Ser Gly Leu Tyr Glu  
                     555                    560                    565  
  
 CCA ATG GTT GGG GAA CAG CCC CCT CCA CTC CTG GAG GAG GAG AGA GAG 1843  
 Pro Met Val Gly Glu Gln Pro Pro Pro Leu Leu Glu Glu Glu Arg Glu  
                     570                    575                    580  
  
 ACA GTC ATG TGACCCATAT C 1863  
 Thr Val Met  
                     585

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2051  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 3:

GCGCGGGGGCC GCGGCGGGCGA GCTCGGAGGC CGGCGGCGGC TGCCCCGAGG GACGCGGGCCC 60  
 TAGGCGGTGG CG ATG GGG GCC GCC CGG ATC GCA CCC AGC CTG GCG CTC 108  
                     Met Gly Ala Ala Arg Ile Ala Pro Ser Leu Ala Leu  
                     1                    5                    10  
  
 CTA CTC TGC TGC CCA GTG CTC AGC TCC GCA TAT GCG CTG GTG GAT GCG 156  
 Leu Leu Cys Cys Pro Val Leu Ser Ser Ala Tyr Ala Leu Val Asp Ala  
                     15                    20                    25  
  
 GAC GAT GTC TTT ACC AAA GAG GAA CAG ATT TTC CTG CTG CAC CGT GCC 204  
 Asp Asp Val Phe Thr Lys Glu Glu Gln Ile Phe Leu Leu His Arg Ala  
                     30                    35                    40  
  
 CAG GCG CAA TGT GAC AAG CTG CTC AAG GAA GTT CTG CAC ACA GCA GCC 252  
 Gln Ala Gln Cys Asp Lys Leu Leu Lys Glu Val Leu His Thr Ala Ala  
                     45                    50                    55                    60  
  
 AAC ATA ATG GAG TCA GAC AAG GGC TGG ACA CCA GCA TCT ACG TCA GGG 300  
 Asn Ile Met Glu Ser Asp Lys Gly Trp Thr Pro Ala Ser Thr Ser Gly  
                     65                    70                    75  
  
 AAG CCC AGG AAA GAG AAG GCA TCG GGA AAG TTC TAC CCT GAG TCT AAA 348  
 Lys Pro Arg Lys Glu Lys Ala Ser Gly Lys Phe Tyr Pro Glu Ser Lys  
                     80                    85                    90  
  
 GAG AAC AAG GAC GTG CCC ACC GGC AGC AGG CGC AGA GGG CGT CCC TGT 396  
 Glu Asn Lys Asp Val Pro Thr Gly Ser Arg Arg Arg Gly Arg Pro Cys  
                     95                    100                    105

- 58 -

CTG CCC GAG TGG GAC AAC ATC GTT TGC TGG CCA TTA GGG GCA CCA GGT Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Leu Gly Ala Pro Gly 110 115 120	444
GAA GTG GTG GCA GTA CCT TGT CCC GAT TAC ATT TAT GAC TTC AAT CAC Glu Val Val Ala Val Pro Cys Pro Asp Tyr Ile Tyr Asp Phe Asn His 125 130 135 140	492
AAA GGC CAT GCC TAC AGA CGC TGT GAC CGC AAT GGC AGC TGG GAG GTG Lys Gly His Ala Tyr Arg Cys Asp Arg Asn Gly Ser Trp Glu Val 145 150 155	540
GTT CCA GGG CAC AAC CGG ACG TGG GCC AAC TAC AGC GAG TGC CTC AAG Val Pro Gly His Asn Arg Thr Trp Ala Asn Tyr Ser Glu Cys Leu Lys 160 165 170	588
TTC ATG ACC AAT GAG ACG CGG GAA CGG GAG GTA TTT GAC CGC CTA GGC Phe Met Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp Arg Leu Gly 175 180 185	636
ATG ATC TAC ACC GTG GGA TAC TCC ATG TCT CTC GCC TCC CTC ACG GTG Met Ile Tyr Thr Val Gly Tyr Ser Met Ser Leu Ala Ser Leu Thr Val 190 195 200	684
GCT GTG CTC ATC CTG GCC TAT TTT AGG CGG CTG CAC TGC ACG CGC AAC Ala Val Leu Ile Leu Ala Tyr Phe Arg Arg Leu His Cys Thr Arg Asn 205 210 215 220	732
TAC ATC CAC ATG CAC ATG TTC CTG TCG TTT ATG CTG CGC GCC GCG AGC Tyr Ile His Met His Met Phe Leu Ser Phe Met Leu Arg Ala Ala Ser 225 230 235	780
ATC TTC GTG AAG GAC GCT GTG CTC TAC TCT GGC TTC ACG CTG GAT GAG Ile Phe Val Lys Asp Ala Val Leu Tyr Ser Gly Phe Thr Leu Asp Glu 240 245 250	828
GCC GAG CGC CTC ACA GAG GAA GAG TTG CAC ATC ATC GCG CAG GTG CCA Ala Glu Arg Leu Thr Glu Glu Glu Leu His Ile Ile Ala Gln Val Pro 255 260 265	876
CCT CCG CCG GCC GCT GCC GCC GTA GGC TAC GCT GGC TGC CGC GTG GCG Pro Pro Pro Ala Ala Ala Ala Val Gly Tyr Ala Gly Cys Arg Val Ala 270 275 280	924
GTG ACC TTC TTC CTC TAC TTC CTG GCT ACC AAC TAC TAC TGG ATT CTG Val Thr Phe Phe Leu Tyr Phe Leu Ala Thr Asn Tyr Tyr Trp Ile Leu 285 290 295 300	972
GTG GAG GGG CTG TAC TTG CAC AGC CTC ATC TTC ATG GCC TTT TTC TCA Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser 305 310 315	1020

- 59 -

GAG AAG AAG TAC CTG TGG GGC TTC ACC ATC TTT GGC TGG GGT CTA CCG	1068
Glu Lys Lys Tyr Leu Trp Gly Phe Thr Ile Phe Gly Trp Gly Leu Pro	
320 325 330	
GCT GTC TTC GTG GCT GTG TGG GTC GGT GTC AGA GCA ACC TTG GCC AAC	1116
Ala Val Phe Val Ala Val Trp Val Gly Val Arg Ala Thr Leu Ala Asn	
335 340 345	
ACT GGG TGC TGG GAT CTG AGC TCC GGG CAC AAG AAG TGG ATC ATC CAG	1164
Thr Gly Cys Trp Asp Leu Ser Ser Gly His Lys Lys Trp Ile Ile Gln	
350 355 360	
GTG CCC ATC CTG GCA TCT GTT GTG CTC AAC TTC ATC CTT TTT ATC AAC	1212
Val Pro Ile Leu Ala Ser Val Val Leu Asn Phe Ile Leu Phe Ile Asn	
365 370 375 380	
ATC ATC CGG GTG CTT GCC ACT AAG CTT CGG GAG ACC AAT GCG GGC CGG	1260
Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg	
385 390 395	
TGT GAC ACC AGG CAG CAG TAC CGG AAG CTG CTC AGG TCC ACG TTG GTG	1308
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Arg Ser Thr Leu Val	
400 405 410	
CTC GTG CCG CTC TTT GGT GTC CAC TAC ACC GTC TTC ATG GCC TTG CCG	1356
Leu Val Pro Leu Phe Gly Val His Tyr Thr Val Phe Met Ala Leu Pro	
415 420 425	
TAC ACC GAG GTC TCA GGG ACA TTG TGG CAG ATC CAG ATG CAT TAT GAG	1404
Tyr Thr Glu Val Ser Gly Thr Leu Trp Gln Ile Gln Met His Tyr Glu	
430 435 440 445	
ATG CTC TTC AAC TCC TTC CAG GGA TTT TTT GTT GCC ATC ATA TAC TGT	1452
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
450 455 460	
TTC TGC AAT GGT GAG GTG CAG GCA GAG ATT AGG AAG TCA TGG AGC CGC	1500
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Arg Lys Ser Trp Ser Arg	
465 470 475	
TGG ACA CTG GCG TTG GAC TTC AAG CGC AAA GCA CGA AGT GGG AGT AGC	1548
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
480 485 490	
AGC TAC AGC TAT GGC CCA ATG GTG TCT CAC ACG AGT GTG ACC AAT GTG	1596
Ser Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
495 500 505	
GGC CCC CGT GCA GGA CTC AGC CTC CCC CTC AGC CCC CGC CTG CCT CCT	1644
Gly Pro Arg Ala Gly Leu Ser Leu Pro Leu Ser Pro Arg Leu Pro Pro	
510 515 520 525	

- 60 -

GCC ACT ACC AAT GGC CAC TCC CAG CTG CCT GGC CAT GCC CCA GGG Ala Thr Thr Asn Gly His Ser Gln Leu Pro Gly His Ala Lys Pro Gly	1692
530 535 540	
GCT CCA GCC ACT GAG ACT GAA ACC CTA CCA GTC ACT ATG GCG GTT CCC Ala Pro Ala Thr Glu Thr Glu Thr Leu Pro Val Thr Met Ala Val Pro	1740
545 550 555	
AAG GAC GAT GGA TTC CTT AAC GGC TCC TGC TCA GGC CTG GAT GAG GAG Lys Asp Asp Gly Phe Leu Asn Gly Ser Cys Ser Gly Leu Asp Glu Glu	1788
560 565 570	
GCC TCC GGG TCT GCG CGG CCG CCT CCA TTG TTG CAG GAA GGA TGG GAA Ala Ser Gly Ser Ala Arg Pro Pro Pro Leu Leu Gln Glu Gly Trp Glu	1836
575 580 585	
ACA GTC ATG TGACTGGGCA CTAGGGGGCT AGACTGCTGG CCTGGGCACA Thr Val Met	1885
590	
TGGACAGATG GACCAAGAAG CCAGTGTTTG GCTGGTTGTC TATTCGGGAT CTGGACCAGG	1945
AAGATAACAA AAGGAAAATG GAAGTGGACG AAGCAGAGAA GAAGGAAGAG GTTTTGCAGG	2005
AATTAAATAT GTTTCCTCAG TTGGATGATG AGGACACAAG GAAGGC	2051

What is claimed is:

- 61 -

Claims

1           1.     Isolated DNA comprising a DNA sequence  
2 encoding a cell receptor of a vertebrate animal, said  
3 receptor having an amino acid sequence with at least 30%  
4 identity to the amino acid sequence shown in FIG. 3.

1           2.     The isolated DNA of claim 1, wherein said  
2 DNA sequence encodes substantially all of the amino acid  
3 sequence shown in FIG. 1 (SEQ. ID NO. 1).

1           3.     The isolated DNA of claim 1, wherein said  
2 DNA sequence encodes substantially all of the amino acid  
3 sequence shown in FIG. 3 (SEQ. ID NO. 3).

1           4.     The isolated DNA of claim 1, said isolated  
2 DNA being (8A6), deposited with the ATCC and designated  
3 ATCC Accession No. 68570.

1           5.     The isolated DNA of claim 1, wherein said  
2 DNA sequence encodes substantially all of the amino acid  
3 sequence shown in Fig. 6 (SEQ. ID. NO. 4).

1           6.     The isolated DNA of claim 1, wherein said  
2 DNA sequence hybridizes to the DNA sequence shown in Fig.  
3 1 (SEQ. ID NO. 1).

1           7.     The isolated DNA of claim 1, wherein said  
2 DNA sequence hybridizes to the DNA sequence shown in Fig.  
3 3 (SEQ. ID NO. 3).

1           8.     The isolated DNA of claim 1, wherein said  
2 DNA sequence hybridizes to the DNA sequence shown in Fig.  
3 6 (SEQ. ID NO. 4).

- 62 -

1           9.    A purified preparation of a vector, said  
2 vector comprising a DNA sequence encoding a parathyroid  
3 hormone receptor.

1           10.   A cell containing the isolated DNA of claim  
2 1.

1           11.   The cell of claim 10, wherein said cell is  
2 capable of expressing said cell receptor from said  
3 isolated DNA.

1           12.   An essentially homogenous population of  
2 cells, each of which comprises the isolated DNA of claim  
3 1.

1           13.   Isolated DNA comprising a DNA sequence  
2 encoding a polypeptide capable of binding parathyroid  
3 hormone or parathyroid-hormone-related protein.

1           14.   A method for producing a polypeptide, said  
2 method comprising:  
3                providing a cell comprising isolated DNA  
4 encoding a parathyroid hormone receptor or a fragment  
5 thereof; and  
6                culturing said cell under conditions  
7 permitting expression of a polypeptide from said DNA.

1           15.   A single-stranded DNA comprising a portion  
2 of a parathyroid hormone receptor gene, said portion  
3 being at least 18 nucleotides long.

1           16.   The single-stranded DNA of claim 15, wherein  
2 said portion is less than all of said parathyroid hormone  
3 receptor gene.

- 63 -

1           17. The single-stranded DNA of claim 15, wherein  
2 said DNA is detectably labeled.

1           18. A single-stranded DNA comprising a portion  
2 of a parathyroid hormone receptor cDNA, said portion  
3 being at least 18 nucleotides long.

1           19. The single-stranded DNA of claim 18, wherein  
2 said DNA is antisense.

1           20. Parathyroid hormone receptor produced by  
2 expression of a recombinant DNA molecule encoding a  
3 parathyroid hormone receptor.

1           21. An essentially purified preparation of the  
2 parathyroid hormone receptor of claim 20.

1           22. An essentially purified preparation of the  
2 parathyroid receptor produced by the expression of the  
3 DNA of claim 5.

1           23. A polypeptide comprising at least six amino  
2 acids and less than the complete amino acid sequence of a  
3 parathyroid hormone receptor, said polypeptide capable of  
4 binding parathyroid hormone or parathyroid hormone-  
5 related protein.

1           24. The polypeptide of claim 23, wherein said  
2 parathyroid hormone receptor is a human parathyroid  
3 receptor.

1           25. The polypeptide of claim 23, wherein said  
2 fragment comprises

- 3           (a) TNETREREVFDRLGMIYTVG,  
4           (b) YLYSGFTLDEAERLTEEEL,

- 64 -

- 5 (c) VTFFLYFLATNYYWILVEG,  
6 (d) Y-RATLANTGCWDLSSGHKKWIIQVP,  
7 (e) PYTEYSGTLWQIQMHYEM,  
8 (f) DDVFTKEEQIFLLHRAQA,  
9 (g) FFRLHCTRNY,  
10 (h) EKKYLWGFTL,  
11 (i) VLATKLRETNAGRCDTROQYRKLLK, or  
12 (j) a fragment of (a) - (i) which is capable of  
13 binding parathyroid hormone or parathyroid hormone-  
14 related protein.

1 26. A therapeutic composition comprising, in a  
2 pharmaceutically-acceptable carrier, (a) a parathyroid  
3 hormone receptor or (b) a polypeptide comprising a  
4 fragment of said receptor.

1 27. An antibody capable of forming an immune  
2 complex with a parathyroid hormone receptor.

1 28. A therapeutic composition comprising the  
2 antibody of claim 27 and a pharmaceutically-acceptable  
3 carrier.

1 29. A method of reducing the level of calcium in  
2 the blood of a mammal, which method comprises  
3 administering the therapeutic composition of claim 26 to  
4 said mammal in a dosage effective to inhibit activation  
5 by parathyroid hormone or parathyroid hormone-related  
6 protein of a parathyroid hormone receptor of said mammal.

1 30. A method of reducing the level of calcium in  
2 the blood of a mammal, which method comprises  
3 administering the therapeutic composition of claim 28 to  
4 said mammal in a dosage effective to inhibit activation

- 65 -

5 by parathyroid hormone or parathyroid hormone-related  
6 protein of a parathyroid hormone receptor of said mammal.

1 31. A method for identifying a compound capable  
2 of competing with a parathyroid hormone for binding to a  
3 parathyroid hormone receptor, said method comprising:

4 (a) contacting the polypeptide of claim 23 with  
5 a parathyroid hormone, (i) in the presence or (ii) in the  
6 absence of a candidate compound; and

7 (b) comparing (i) the level of binding of said  
8 polypeptide to said parathyroid hormone in the presence  
9 of said candidate compound, with (ii) the level of  
10 binding of said polypeptide to said parathyroid hormone  
11 in the absence of said candidate compound; a lower level  
12 of binding in the presence of said candidate compound  
13 than in its absence indicating that said candidate  
14 compound is capable of competing with said parathyroid  
15 hormone for binding to said receptor.

1 32. A method for identifying a compound capable  
2 of competing with a parathyroid hormone-related protein  
3 for binding to a parathyroid hormone receptor, said  
4 method comprising:

5 (a) contacting the polypeptide of claim 23 with  
6 a parathyroid hormone-related protein, (i) in the  
7 presence or (ii) in the absence of a candidate compound;  
8 and

9 (b) comparing (i) the level of binding of said  
10 polypeptide to said parathyroid hormone-related protein  
11 in the presence of said candidate compound, with (ii) the  
12 level of binding of said polypeptide to said parathyroid  
13 hormone-related protein in the absence of said candidate  
14 compound; a lower level of binding in the presence of  
15 said candidate compound than in its absence indicating  
16 that said candidate compound is capable of competing with

- 66 -

17 said parathyroid hormone-related protein for binding to  
18 said receptor.

1           33. A method for identifying a compound capable  
2 of competing with a parathyroid hormone for binding to a  
3 parathyroid hormone receptor, said method comprising:  
4           (a) combining a parathyroid hormone with the  
5 cell of claim 11, (i) in the presence or (ii) in the  
6 absence of a candidate compound; and  
7           (b) comparing (i) the level of binding of said  
8 receptor to said parathyroid hormone in the presence of  
9 said candidate compound, with (ii) the level of binding  
10 of said receptor to said parathyroid hormone in the  
11 absence of said candidate compound; a lower level of  
12 binding in the presence of said candidate compound than  
13 in its absence indicating that said candidate compound is  
14 capable of competing with said parathyroid hormone for  
15 binding to said receptor.

1           34. A compound capable of inhibiting the binding  
2 of parathyroid hormone or parathyroid hormone-related  
3 protein to a parathyroid receptor on the surface of a  
4 cell.

1           35. A therapeutic composition comprising the  
2 compound of claim 34 and a pharmaceutically-acceptable  
3 carrier.

1           36. A method for identifying a DNA sequence  
2 homologous to a parathyroid hormone receptor-encoding DNA  
3 sequence, said method comprising:  
4           providing a genomic or cDNA library;  
5           contacting said library with the single-  
6 stranded DNA of claim 18, under conditions permitting

- 67 -

7 hybridization between said single-stranded DNA and a  
8 homologous DNA sequence in said library; and  
9 identifying a clone from said library which  
10 hybridizes to said single-stranded DNA, said  
11 hybridization being indicative of the presence in said  
12 clone of a DNA sequence homologous to a parathyroid  
13 hormone receptor-encoding DNA sequence.

1 37. A transgenic non-human vertebrate animal  
2 bearing a transgene comprising a DNA sequence encoding  
3 parathyroid hormone receptor or a fragment thereof.

1 38. A diagnostic method comprising:  
2 (a) obtaining a first blood sample from an  
3 animal; (b) administering the composition of claim  
4 35 to said animal;  
5 (c) obtaining a second blood sample from said  
6 animal subsequent to said administration of said  
7 composition; and  
8 (d) comparing the calcium level in said first  
9 blood sample with that in said second blood sample, a  
10 lower calcium level in said second blood sample being  
11 diagnostic for a parathyroid hormone-related condition.

12 39. The isolated DNA of claim 1, wherein said  
13 DNA sequence encodes a parathyroid hormone receptor.

1  
2 40. The parathyroid hormone receptor of claim 20  
3 for use in therapy or diagnosis.

4 41. The polypeptide of claim 23 for use in  
5 therapy or diagnosis.

6 42. The antibody of claim 27 for use in therapy  
7 or diagnosis.

- 68 -

8           43. The therapeutic composition of claim 26 for  
9 use in therapy for the inhibition of activation by  
10 parathyroid hormone or parathyroid hormone-related  
11 protein of a parathyroid hormone receptor of a mammal or  
12 for the reduction of the level of calcium in the blood of  
13 a mammal.

14           44. The therapeutic composition of claim 28 for  
15 use in therapy for the inhibition of activation by  
16 parathyroid hormone or parathyroid hormone-related  
17 protein of a parathyroid hormone receptor of a mammal or  
18 for the reduction of the level of calcium in the blood of  
19 a mammal.

20           45. The parathyroid hormone receptor of claim 20  
21 for use in the manufacture of a medicament for use in  
22 therapy for the inhibition of activation by parathyroid  
23 hormone or parathyroid hormone-related protein of a  
24 parathyroid hormone receptor of a mammal or for the  
25 reduction of the level of calcium in the blood of a  
26 mammal.

27           46. The polypeptide of claim 23 for use in the  
28 manufacture of a medicament for use in therapy for the  
29 inhibition of activation by parathyroid hormone or  
30 parathyroid hormone-related protein of a parathyroid  
31 hormone receptor of a mammal or for the reduction of the  
32 level of calcium in the blood of a mammal.

33           47. The antibody of claim 27 for use in the  
34 manufacture of a medicament for use in therapy for the  
35 inhibition of activation by parathyroid hormone or  
36 parathyroid hormone-related protein of a parathyroid  
37 hormone receptor of a mammal or for the reduction of the  
38 level of calcium in the blood of a mammal.

- 69 -

39           48. A method for identifying a hypercalcemic  
40 condition in a patient which is mediated by parathyroid  
41 hormone or parathyroid hormone-related protein, the  
42 method comprising

43           (a) determining the calcium level of a first  
44 blood sample from the patient,

45           (b) determining the calcium level of a second  
46 blood sample from the patient taken at a time subsequent  
47 after administration of the therapeutic composition of  
48 claim 26, and

49           (c) comparing the calcium levels of the two  
50 blood samples, a lower calcium level in the second blood  
51 sample being indicative of a condition related to  
52 parathyroid hormone or parathyroid hormone-related  
53 protein in the patient.

54           49. A method for identifying a hypercalcemic  
55 condition in a patient which is mediated by parathyroid  
56 hormone or parathyroid hormone-related protein, the  
57 method comprising

58           (a) determining the calcium level of a first  
59 blood sample from the patient,

60           (b) determining the calcium level of a second  
61 blood sample from the patient taken at a subsequent time  
62 after administration of the therapeutic composition of  
63 claim 28, and

64           (c) comparing the calcium levels of the two  
65 blood samples, a lower calcium level in the second blood  
66 sample being indicative of a condition related to  
67 parathyroid hormone or parathyroid hormone-related  
68 protein in the patient.

FIG. 1

TGGGCACAGC	CACCCTGTTG	GTAGTCCAGG	GGCCAGCCCA	CTGAGCTGGC	ATATCAGCTG	60
GTGGCCCCGT	TGGACTCGGC	CCTAGGGAAC	GGCGGCG	ATG GGA GCG CCC CGG ATC		115
				Met Gly Ala Pro Arg Ile		
				1 5		
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC						150
Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val						
	10		15		20	
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC						215
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile						
	25		30		35	
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG						255
Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu						
	40		45		50	
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA						307
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser						
	55		60		65	70
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC						355
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro						
	75		80		85	
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT						403
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp						
	90		95		100	
EGC TTC TGC CTA COT GAG TGG AAC AAC ATT GTG TGC TGG COT GCT GGA						415
Gly Phe Cys Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Ala Gly						
	105		110		115	
GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC						499
Val Pro Gly Lys Val Val Ala Val Pro Cys Pro Asp Tyr Phe Tyr Asp						
	120		125		130	
TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC						547
Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser						
	135		140		145	150
TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA						595
Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu						
	155		160		165	
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT						643
Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp						
	170		175		180	

FIG. 1

CGC	CTC	GGA	ATG	ATC	TAC	ACT	GTG	GGC	TAC	TCC	ATC	TCT	CTG	GGC	TCC	691
Arg	Leu	Gly	Met	Ile	Tyr	Thr	Val	Gly	Tyr	Ser	Ile	Ser	Leu	Gly	Ser	
		185						190					195			
CTC	ACT	GTG	GCT	GTG	CTG	ATT	CTG	GGT	TAC	TTT	AGG	AGG	TTA	CAT	TGC	739
Leu	Thr	Val	Ala	Val	Leu	Ile	Leu	Gly	Tyr	Phe	Arg	Arg	Leu	His	Cys	
	200					205					210					
ACC	CGA	AAC	TAC	ATT	CAC	ATG	CAT	CTC	TTC	GTG	TCC	TTT	ATG	CTC	CGG	787
Thr	Arg	Asn	Tyr	Ile	His	Met	His	Leu	Phe	Val	Ser	Phe	Met	Leu	Arg	
	215				220					225					230	
GCT	GTA	AGC	ATC	TTC	ATC	AAG	GAT	GCT	GTG	CTC	TAC	TCG	GGG	GTT	TCC	835
Ala	Val	Ser	Ile	Phe	Ile	Lys	Asp	Ala	Val	Leu	Tyr	Ser	Gly	Val	Ser	
				235					240					245		
ACA	GAT	GAA	ATC	GAG	CGC	ATC	ACC	GAG	GAG	GAG	CTG	AGG	GCC	TTC	ACA	883
Thr	Asp	Glu	Ile	Glu	Arg	Ile	Thr	Glu	Glu	Glu	Leu	Arg	Ala	Phe	Thr	
			250					255					260			
GAG	CCT	CCC	CCT	GCT	GAC	AAG	GGG	GGT	TTT	GTG	GGC	TGC	AGA	GTG	GCG	931
Glu	Pro	Pro	Pro	Ala	Asp	Lys	Ala	Gly	Phe	Val	Gly	Cys	Arg	Val	Ala	
		265					270					275				
GTA	ACC	GTC	TTC	CTT	TAC	TTC	CTG	ACC	ACC	AAC	TAC	TAC	TGG	ATC	CTG	979
Val	Thr	Val	Phe	Leu	Tyr	Phe	Leu	Thr	Thr	Asn	Tyr	Tyr	Trp	Ile	Leu	
	280					285					290					
GTG	GAA	GGC	CTC	TAC	CTT	CAC	AGC	CTC	ATC	TTC	ATG	GCT	TTT	TTC	TCT	1027
Val	Glu	Gly	Leu	Tyr	Leu	His	Ser	Leu	Ile	Phe	Met	Ala	Phe	Phe	Ser	
	295				300					305					310	
GAG	AAA	AAG	TAT	CTC	TGG	GGT	TTC	ACA	TTA	TTT	GGC	TGG	GGC	CTC	CCT	1075
Glu	Lys	Lys	Tyr	Leu	Trp	Gly	Phe	Thr	Leu	Phe	Gly	Trp	Gly	Leu	Pro	
				315					320					325		
ACC	GTG	TTT	CTC	GCT	GTG	TGG	ATC	ACC	GTG	AGG	GCT	ACA	CTG	GCC	AAC	1123
Ala	Val	Phe	Val	Ala	Val	Trp	Val	Thr	Val	Arg	Ala	Thr	Leu	Ala	Asn	
			330					335					340			
ACT	GAG	TGC	TGG	GAC	CTG	AGT	TCC	GGG	AAT	AAG	AAA	TGG	ATC	ATA	CAG	1171
Thr	Glu	Cys	Trp	Asp	Leu	Ser	Ser	Gly	Asn	Lys	Lys	Trp	Ile	Ile	Gln	
		345					350					355				
GTG	CCC	ATC	CTG	GCA	GCT	ATT	GTG	CTC	AAC	TTT	ATT	CTT	TTT	ATC	AAT	1219
Val	Pro	Ile	Leu	Ala	Ala	Ile	Val	Val	Asn	Phe	Ile	Leu	Phe	Ile	Asn	
	360					365					370					
ATA	ATC	AGA	GTC	CTG	GCT	ACT	AAA	CTC	GGG	GAG	ACC	AAT	GCA	GGG	AGA	1267
Ile	Ile	Arg	Val	Leu	Ala	Thr	Lys	Leu	Arg	Glu	Thr	Asn	Ala	Gly	Arg	
	375				380					385					390	

[illegible]

1 of 3

4/30

FIG. 2

TTGGGCACAGC	CACCCCTGTTG	GTAGTCCAGG	GGCCAGCCCCA	CTGAGCTGGC	ATATCAGCTG	60
GTGGCCCCCGT	TGGACTCGGC	CCTAGGGAAC	GGCGGCG	ATG GGA GCG CCC CGG ATC	Met Gly Ala Pro Arg Ile	115
				1	5	
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC	Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val	10	15	20		163
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC	Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile	25	30	35		211
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG	Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu	40	45	50		259
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA	Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser	55	60	65	70	307
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC	Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro	75	80	85		355
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT	Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp	90	95	100		403
GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA	Gly Phe Cys Leu Pro Glu Trp Ser Ser Ile Val Cys Trp Pro Ala Gly	105	110	115		451
GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC	Val Pro Gly Lys Val Val Ala Val Val Cys Pro Asp Tyr Phe Tyr Asp	120	125	130		499
TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC	Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser	135	140	145	150	547
TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA	Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu	155	160	165		595
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT	Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Glu Glu Val Phe Asp	170	175	180		643

5/30

2 of 2

FIG. 2

CGC	CTC	GGA	ATG	ATC	TAC	ACT	GTG	GGC	TAC	TCC	ATC	TCT	CTG	GGC	TCC	691
Arg	Leu	Gly	Met	Ile	Tyr	Thr	Val	Gly	Tyr	Ser	Ile	Ser	Leu	Gly	Ser	
		185					190					195				
CTC	ACT	GTG	GCT	GTG	CTG	ATT	CTG	GGT	TAC	TTT	AGG	AGG	TTA	CAT	TGC	703
Leu	Thr	Val	Ala	Val	Leu	Ile	Leu	Gly	Tyr	Phe	Arg	Arg	Leu	His	Cys	
	200					205					210					
ACC	CGA	AAC	TAC	ATT	CAC	ATG	CAT	CTC	TTC	GTG	TCC	TTT	ATG	CTC	CGG	737
Thr	Arg	Asn	Tyr	Ile	His	Met	His	Leu	Phe	Val	Ser	Phe	Met	Leu	Arg	
	215				220					225					230	
GCT	GTA	AGC	ATC	TTC	ATC	AAG	GAT	GCT	GTG	CTC	TAC	TCG	GGG	GTT	TCC	835
Ala	Val	Ser	Ile	Phe	Ile	Lys	Asp	Ala	Val	Leu	Tyr	Ser	Gly	Val	Ser	
				235					240					245		
ACA	GAT	GAA	ATC	GAG	CGC	ATC	ACC	GAG	GAG	GAG	CTG	AGG	GCC	TTC	ACA	883
Thr	Asp	Glu	Ile	Glu	Arg	Ile	Thr	Glu	Glu	Glu	Leu	Arg	Ala	Phe	Thr	
		250						255					260			
GAG	CCT	CCC	CCT	GCT	GAC	AAG	GCG	GGT	TTT	GTG	GGC	TGC	AGA	GTG	GCG	931
Glu	Pro	Pro	Pro	Ala	Asp	Lys	Ala	Gly	Phe	Val	Gly	Cys	Arg	Val	Ala	
		265					270					275				
GTA	ACC	GTC	TTC	CTT	TAC	TTC	CTG	ACC	ACC	AAC	TAC	TAC	TGG	ATC	CTG	979
Val	Thr	Val	Phe	Leu	Tyr	Phe	Leu	Thr	Thr	Asn	Tyr	Tyr	Trp	Ile	Leu	
	280					285					290					
GTG	GAA	GGC	CTC	TAC	CTT	CAC	AGC	CTC	ATC	TTC	ATG	GCT	TTT	TTC	TCT	1027
Val	Glu	Gly	Leu	Tyr	Leu	His	Ser	Leu	Ile	Phe	Met	Ala	Phe	Phe	Ser	
	295				300					305					310	
GAG	AAA	AAG	TAT	CTC	TGG	GGT	TTC	ACA	TTA	TTT	GGC	TGG	GGC	CTC	CCT	1075
Glu	Lys	Lys	Tyr	Leu	Trp	Gly	Phe	Thr	Leu	Phe	Gly	Trp	Gly	Leu	Pro	
				315					320					325		
GCC	GTG	TTT	GTC	GCT	GTG	TGG	GTG	ACC	GTG	AGG	GCT	ACA	CTG	GCC	AAC	1123
Ala	Val	Phe	Val	Ala	Val	Trp	Val	Thr	Val	Arg	Ala	Thr	Leu	Ala	Asn	
			330				335						340			
ACT	GAG	TGC	TGG	GAC	CTG	AGT	TCG	GGG	AAT	AAG	AAA	TGG	ATC	ATA	CAG	1171
Thr	Glu	Cys	Trp	Asp	Leu	Ser	Ser	Gly	Asn	Lys	Lys	Trp	Ile	Ile	Gln	
		345					350					355				
GTG	CCC	ATC	CTG	GCA	GCT	ATT	GTG	GTG	AAC	TTT	ATT	CTT	TTT	ATC	AAT	1219
Val	Pro	Ile	Leu	Ala	Ala	Ile	Val	Val	Asn	Phe	Ile	Leu	Phe	Ile	Asn	
	360					365					370					
ATA	ATC	AGA	GTC	CTG	GCT	ACT	AAA	CTC	CGG	GAG	ACC	AAT	GCA	GGG	AGA	1267
Ile	Ile	Arg	Val	Leu	Ala	Thr	Lys	Leu	Arg	Glu	Thr	Asn	Ala	Gly	Arg	
	375				380					385					390	

3 of 3

FIG. 2

TGT Cys	GAC Asp	ACG Thr	AGG Arg	CAA Gln 395	CAG Gln	TAT Tyr	AGA Arg	AAG Lys	CTG Leu 400	CTG Leu	AAG Lys	TCC Ser	ACG Thr	CTA Leu 405	GTC Val	1315
CTC Leu	ATG Met	CCG Pro	CTA Leu 410	TTT Phe	GGG Gly	GTG Val	CAC His	TAC Tyr 415	ATC Ile	GTC Val	TTC Phe	ATG Met 420	GCC Ala	ACG Thr	CCG Pro	1363
TAC Tyr	ACA Thr	GAA Glu 425	GTA Val	TCA Ser	GGG Gly	ATT Ile	CTT Leu 430	TGG Trp	CAA Gln	GTC Val	CAA Gln	ATG Met 435	CAC His	TAT Tyr	GAA Glu	1411
ATG Met	CTC Leu 440	TTC Phe	AAT Asn	TCA Ser	TTC Phe	CAG Gln 445	GGA Gly	TTT Phe	TTC Phe	GTT Val	GCC Ala 450	ATT Ile	ATA Ile	TAC Tyr	TGT Cys	1459
TTC Phe 455	TGC Cys	AAT Asn	GGA Gly	GAG Glu 460	GTA Val	CAA Gln	GCA Ala	GAG Glu	ATC Ile	AAG Lys 465	AAG Lys	TCA Ser	TGG Trp	AGC Ser	CGA Arg 470	1507
TGG Trp	ACC Thr	CTG Leu	GCC Ala	TTG Leu 475	GAC Asp	TTC Phe	AAG Lys	CGG Arg	AAG Lys 480	GCC Ala	CGG Arg	AGT Ser	GGC Gly	AGC Ser 485	AGT Ser	1555
ACC Thr	TAC Tyr	AGC Ser	TAT Tyr 490	GGC Gly	CCC Pro	ATG Met	GTG Val	TCA Ser 495	CAT His	ACA Thr	AGT Ser	GTC Val	ACC Thr 500	AAT Asn	GTG Val	1603
GGA Gly	CCT Pro	CGA Arg 505	GGG Gly	GGG Gly	CTG Leu	GCC Ala	TTG Leu 510	TCC Ser	CTC Leu	AGC Ser	CCT Pro	CGA Arg 515	CTA Leu	GCT Ala	CCT Pro	1651
GGG Gly 520	GCT Ala	GGA Gly	GCC Ala	AGT Ser	GCC Ala	AAT Asn 525	GGC Gly	CAT His	CAC His	CAG Gln	TTG Leu 530	CCT Pro	GGC Gly	TAT Tyr	GTG Val	1699
AAG Lys 535	CAT His	GGT Gly	TCC Ser	ATT Ile	TCT Ser 540	GAG Glu	AAC Asn	TCA Ser	TTG Leu	CCT Pro 545	TCA Ser	TCT Ser	GGC Gly	CCA Pro	GAG Glu 550	1747
CCT Pro	GGC Gly	ACC Thr	AAA Lys	GAT Asp 555	GAC Asp	GGG Gly	TAT Tyr	CTC Leu	AAT Asn 560	GGC Gly	TCT Ser	GGA Gly	CTT Leu	TAT Tyr 565	GAG Glu	1795
CCA Pro	ATG Met	GTT Val	GGG Gly 570	GAA Glu	CAG Gln	CCC Pro	CCT Pro	CCA Pro 575	CTC Leu	CTG Leu	GAG Glu	GAG Glu	GAG Glu 580	AGA Arg	GAG Glu	1843
ACA Thr	GTC Val	ATG Met 585	TGACCCATAT C													1863

7/30

1 of 3

FIG. 3

GGCGGGGGGCC GCGGCGGCGA GCTCGGAGGC CGGCGGCGGC TGCCCCGAGG GACGCGGCCC 60  
TAGGCGGTGG CG ATG GGG GCC GCC CGG ATC GCA CCC AGC CTG GCG CTC 108  
Met Gly Ala Ala Arg Ile Ala Pro Ser Leu Ala Leu  
1 5 10  
CTA CTC TGC TGC CCA GTG CTC AGC TCC GCA TAT GCG CTG GTG GAT GCG 126  
Leu Leu Cys Cys Pro Val Leu Ser Ser Ala Tyr Ala Leu Val Asp Ala  
15 20 25  
GAC GAT GTC TTT ACC AAA GAG GAA CAG ATT TTC CTG CTG CAC CGT GCC 204  
Asp Asp Val Phe Thr Lys Glu Glu Gln Ile Phe Leu Leu His Arg Ala  
30 35 40  
CAG GCG CAA TGT GAC AAG CTG CTC AAG GAA GTT CTG CAC ACA GCA GCC 222  
Gln Ala Gln Cys Asp Lys Leu Leu Lys Glu Val Leu His Thr Ala Ala  
45 50 55 60  
AAC ATA ATG GAG TCA GAC AAG GGC TGG ACA CCA GCA TCT ACG TCA GGG 300  
Asn Ile Met Glu Ser Asp Lys Gly Trp Thr Pro Ala Ser Thr Ser Gly  
65 70 75  
AAG CCC AGG AAA GAG AAG GCA TCG GGA AAG TTC TAC CCT GAG TCT AAA 348  
Lys Pro Arg Lys Glu Lys Ala Ser Gly Lys Phe Tyr Pro Glu Ser Lys  
80 85 90  
GAG AAC AAG GAC GTG CCC ACC GGC AGC AGG CGC AGA GGG CGT CCC TGT 396  
Glu Asn Lys Asp Val Pro Thr Gly Ser Arg Arg Arg Gly Arg Pro Cys  
95 100 105  
CTG CCC GAG TGG GAC AAC ATC GTT TGC TGG CCA TTA GGG GCA CCA GGT 444  
Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Leu Gly Ala Pro Gly  
110 115 120  
GAA GTG GTG GCA GTA CCT TGT CCC GAT TAC ATT TAT GAC TTC AAT CAC 492  
Glu Val Val Ala Val Pro Cys Pro Asp Tyr Ile Tyr Asp Phe Asn His  
125 130 135 140  
AAA GGC CAT GCC TAC AGA CGC TGT GAC CGC AAT GGC AGC TGG GAG GTG 540  
Lys Gly His Ala Tyr Arg Arg Cys Asp Arg Asn Gly Ser Trp Glu Val  
145 150 155  
GTT CCA GGG CAC AAC CGG ACG TGG GCC AAC TAC AGC GAG TGC CTC AAG 588  
Val Pro Gly His Asn Arg Thr Trp Ala Asn Tyr Ser Glu Cys Leu Lys  
160 165 170  
TTC ATG ACC AAT GAG ACG CGG GAA CGG GAG GTA TTT GAC CGC CTA GGC 636  
Phe Met Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp Arg Leu Gly  
175 180 185  
ATG ATC TAC ACC GTG GGA TAC TCC ATG TCT CTC GCC TCC CTC ACG GTG 684  
Met Ile Tyr Thr Val Gly Tyr Ser Met Ser Leu Ala Ser Leu Thr Val  
190 195 200

8/30

2 of 3

FIG. 3

GCT	GTG	CTC	ATC	CTG	GCC	TAT	TTT	AGG	CGG	CTG	CAC	TGC	ACG	CGC	AAC	732
Ala	Val	Leu	Ile	Leu	Ala	Tyr	Phe	Arg	Arg	Leu	His	Cys	Thr	Arg	Asn	
205					210					215					220	
TAC	ATC	CAC	ATG	CAC	ATG	TTC	CTG	TCG	TTT	ATG	CTG	CGC	GCC	GCG	AGC	780
Tyr	Ile	His	Met	His	Met	Phe	Leu	Ser	Phe	Met	Leu	Arg	Ala	Ala	Ser	
				225					230					235		
ATC	TTC	GTG	AAG	GAC	GCT	GTG	CTC	TAC	TCT	GGC	TTC	ACG	CTG	GAT	GAG	828
Ile	Phe	Val	Lys	Asp	Ala	Val	Leu	Tyr	Ser	Gly	Phe	Thr	Leu	Asp	Glu	
			240					245					250			
GCC	GAG	CGC	CTC	ACA	GAG	GAA	GAG	TTG	CAC	ATC	ATC	GCG	CAG	GTG	CCA	876
Ala	Glu	Arg	Leu	Thr	Glu	Glu	Glu	Leu	His	Ile	Ile	Ala	Gln	Val	Pro	
		255					260					265				
CCT	CCG	CCG	GCC	GCT	GCC	GCC	GTA	GGC	TAC	GCT	GGC	TGC	CGC	GTG	GCG	924
Pro	Pro	Pro	Ala	Ala	Ala	Ala	Val	Gly	Tyr	Ala	Gly	Cys	Arg	Val	Ala	
	270					275					280					
GTG	ACC	TTC	TTC	CTC	TAC	TTC	CTG	GCT	ACC	AAC	TAC	TAC	TGG	ATT	CTG	972
Val	Thr	Phe	Phe	Leu	Tyr	Phe	Leu	Ala	Thr	Asn	Tyr	Tyr	Trp	Ile	Leu	
285				290				295						300		
GTG	GAG	GGG	CTG	TAC	TTG	CAC	AGC	CTC	ATC	TTC	ATG	GCC	TTT	TTC	TCA	1020
Val	Glu	Gly	Leu	Tyr	Leu	His	Ser	Leu	Ile	Phe	Met	Ala	Phe	Phe	Ser	
			305					310					315			
GAG	AAG	AAG	TAC	CTG	TGG	GGC	TTC	ACC	ATC	TTT	GGC	TGG	GGT	CTA	CCG	1068
Glu	Lys	Lys	Tyr	Leu	Trp	Gly	Phe	Thr	Ile	Phe	Gly	Trp	Gly	Leu	Pro	
		320				325						330				
GCT	GTC	TTC	GTG	GCT	GTG	TGG	GTC	GGT	GTC	AGA	GCA	ACC	TTG	GCC	AAC	1116
Ala	Val	Phe	Val	Ala	Val	Trp	Val	Gly	Val	Arg	Ala	Thr	Leu	Ala	Asn	
	335					340					345					
ACT	GGG	TGC	TGG	GAT	CTG	AGC	TCC	AGG	CAC	AAG	AAG	TGG	ATC	ATC	CAG	1164
Thr	Gly	Cys	Trp	Asp	Leu	Ser	Ser	Gly	His	Lys	Lys	Trp	Ile	Ile	Gln	
350				355						360					365	
GTG	CCC	ATC	CTG	GCA	TCT	GTT	GTG	CTC	CAC	TTC	ATC	CTT	TTT	ATC	AAC	1212
Val	Pro	Ile	Leu	Ala	Ser	Val	Val	Leu	Asn	Phe	Ile	Leu	Phe	Ile	Asn	
				370					375					380		
ATC	ATC	CGG	GTG	CTT	GCC	ACT	AAG	CTT	CGG	GAG	ACC	AAT	GCG	GGC	CGG	1260
Ile	Ile	Arg	Val	Leu	Ala	Thr	Lys	Leu	Arg	Glu	Thr	Asn	Ala	Gly	Arg	
			385					390					395			
TGT	GAC	ACC	AGG	CAG	CAG	TAC	CGG	AAG	CTG	CTC	AGG	TCC	ACG	TTG	GTG	1308
Cys	Asp	Thr	Arg	Gln	Gln	Tyr	Arg	Lys	Leu	Leu	Arg	Ser	Thr	Leu	Val	
		400					405					410				

9/30

3 of 3

FIG. 3

CTC GTG CCG CTC TTT GGT GTC CAC TAC ACC GTC TTC ATG GCC TTG CCG Leu Val Pro Leu Phe Gly Val His Tyr Thr Val Phe Met Ala Leu Pro 415 420 425	1356
TAC ACC GAG GTC TCA GGG ACA TTG TGG CAG ATC CAG ATG CAT TAT GAG Tyr Thr Glu Val Ser Gly Thr Leu Trp Gln Ile Gln Met His Tyr Glu 430 435 440 445	1404
ATG CTC TTC AAC TCC TTC CAG GGA TTT TTT GTT GCC ATC ATA TAC TGT Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys 450 455 460	1452
TTC TGC AAT GGT GAG GTG CAG GCA GAG ATT AGG AAG TCA TGG AGC CGC Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Arg Lys Ser Trp Ser Arg 465 470 475	1500
TGG ACA CTG GCG TTG GAC TTC AAG CGC AAA GCA CGA AGT GGG AGT AGC Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser 480 485 490	1548
AGC TAC AGC TAT GGC CCA ATG GTG TCT CAC ACG AGT GTG ACC AAT GTG Ser Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val 495 500 505	1596
GGC CCC CGT GCA GGA CTC AGC CTC CCC CTC AGC CCC CGC CTG CCT CCT Gly Pro Arg Ala Gly Leu Ser Leu Pro Leu Ser Pro Arg Leu Pro Pro 510 515 520 525	1644
GCC ACT ACC AAT GGC CAC TCC CAG CTG CCT GGC CAT GCC AAG CCA GGG Ala Thr Thr Asn Gly His Ser Gln Leu Pro Gly His Ala Lys Pro Gly 530 535 540	1692
GCT CCA GCC ACT GAG ACT GAA ACC CTA CCA GTC ACT ATG GCG GTT CCC Ala Pro Ala Thr Glu Thr Glu Thr Leu Pro Val Thr Met Ala Val Pro 545 550 555	1740
AAG GAC GAT GGA CTC CTT AAC GGC TCC TGC TCA GGC CTG GAT GAG GAG Lys Asp Asp Gly Phe Leu Asn Gly Ser Cys Ser Gly Leu Asp Glu Glu 560 565 570	1788
GCC TCC GGG TCT GCG CGG CCG CCT CCA TTG TTG CAG GAA GGA TGG GAA Ala Ser Gly Ser Ala Arg Pro Pro Pro Leu Leu Gln Glu Gly Trp Glu 575 580 585	1836
ACA GTC ATG TGA CTGGGCA CTAGGGGGCT AGACTGCTGG CCTGGGCACA Thr Val Met 590	1885
TGGACAGATG GACCAAGAAG CCAGTGTTTG GCTGGTTGTC TATTCGGGAT CTGGACCAGG	1945
AAGATAACAA AAGGAAAATG GAAGTGGACG AAGCAGAGAA GAAGGAAGAG GTTTTGCAGG	2005
AATTAAATAT GTTTCCTCAG TTGGATGATG AGGACACAAG GAAGGC	2051

10/30

Fig. 4

```

1 MGAARIAPSLALLCCPVLSAYALVDADDVFTKEZOIFLLHRAQAQCDX 50
  |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
1 MGAPRISHSLALLCCSVLSSVYALVDADDVITKEZOIILLANAQAQCEQ 50
51 LLKEVLHTAANIMESDRGWTPASTSGKPRKEKASGKFPYPSKENKDVP TG 100
  ||||: |||: |||: |||: |||: |||: |||: |||: |||: |||:
51 RLKEVLR.VPELAESAQDW..MSRSATKKEKPAEKLYPQAEZSREVS DR 97
101 SRRRGRPCLPEWONIVCWPLGAPGEVVAVPCPDYIYDFNHRGEBAYRCDR 150
  ||: |||: |||: |||: |||: |||: |||: |||: |||: |||:
98 SRLQDGGCLPEWONIVCWPAQVPGKVVAVPCPDYFYDFNHRGRAYRACDS 147
151 NGSWEVVPGHNRTHANYSECLKFMNTREREVFDRLGHIYTVGYSHSLA 200
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
148 NGSWEVVPGHNRTHANYSECVKPLTNTREREVFDRLGHIYTVGYSHSLG 197
201 SLTVAVLILAYFRRLHCTRNHYIHHMPLSFMLRAASIFVKDAVLYSGFTL 250
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
198 SLTVAVLILGYFRRLHCTRNHYIHHMPLSFMLRAVSIKDAVLYSGVST 247
251 DEAEERLTEEELHIIAQVPPPPAAAAVGYAGCRVAVTFFLYFLATNYWIL 300
  ||: |||: |||: |||: |||: |||: |||: |||: |||: |||:
248 DEIERITEELRAFTZ...PPPADKAGFVGCRVAVTVFLYFLTNYYWIL 294
301 VEGLYLHSLIFMAFFSEKKYLWGFTIFGWLPAVFVAVVWVVRATLANTG 350
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
295 VEGLYLHSLIFMAFFSEKKYLWGFTIFGWLPAVFVAVVWVTVRATLANTE 344
351 CWDLSSGHRKWIIOVPILASVVLNFIIFINI:RVLATKLRETNAGRC DTR 400
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
345 CWDLSSGHRKWIIOVPILAAIVVNFIIFINI:RVLATKLRETNAGRC DTR 394
401 OQYRKLLASTLVLPFGVHYTVFMALPYTEVSGTLWQIQHNYEHLFNSF 450
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
295 OQYRKLLASTLVLPFGVHYIVFMATPYTEVSGTLWQVQHNYEHLFNSF 444
451 QGFFVAIIYCFNGEVOAEIRKSWSRWTLALDFKRRKARSGSSSYSGPHV 500
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
445 QGFFVAIIYCFNGEVOAEIRKSWSRWTLALDFKRRKARSGSSTSYSGPHV 494
501 SHTSVTVVGFPRAGLSPLSPRLFP...ATTNGHSQLPCHAKPGAPATETE 547
  ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||: ||||:
495 SHTSVTVVGFPRGGLALSPLAPGAGASANGHQLPGYVKGHSISENSL 544
548 TLPTVTHAVPRKDDGFLNGSCSGLDEEASGSAAPPPLLQEGWETVM. 591
  |||: |||: |||: |||: |||: |||: |||: |||: |||: |||:
545 PSSGPEPSTKDDGYLNG..SGLYEPHVG.EQPPPLLEEERETVM. 586

```

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396
Quality:	712.2	Length:	595
Ratio:	1.215	Gaps:	6
Percent Similarity:	87.113	Percent Identity:	77.835

11/30

Fig. 5

```

R15 MGAARIAPSL ALLLCCPVLS SAYALVDADD VFTKEEQIFL LHRAQAQCDK 50
OkO MGAPRISHSL ALLLCCSVLS SVYALVDADD VITKEEQIIL LRNAQAQCEQ 50
Okh MGAPRISHSL ALLLCCSVLS SVYALVDADD VITKEEQIIL LRNAQAQCEQ 50
----- A -----

R15 LLKEVLHTAA NIMESDKGWT PASTSGKPRK EKASGKPYPE SKENKDVPTG 100
OkO RLKEVLR.VP ELAESAKDW. .MSRSAKTRK EKPAEKLYPQ AEESREVS DR 97
Okh RLKEVLR.VP ELAESAKDW. .MSRSAKTRK EKPAEKLYPQ AEESREVS DR 97

R15 SRRRGKPCLP EWDNIVCWPL GAPGEVVAVP CPDYIYDFNH KGHAYRRCDR 150
OkO SRLQDGFCLP EWDNIVCWPA GVPKVVAVP CPDYFYDFNH KGRAYRRCD S 147
Okh SRLQDGFCLP EWDNIVCWPA GVPKVVAVP CPDYFYDFNH KGRAYRRCD S 147
----- B -----

N N N N
R15 NGSWEVVPCH NRTWANYSEC LKFMNTRTRE REVFDRLGMI YTVGYSMSLA 200
OkO NGSWEVVPCH NRTWANYSEC VKFLTNETRE REVFDRLGMI YTVGYSISLG 197
Okh NGSWEVVPCH NRTWANYSEC VKFLTNETRE REVFDRLGMI YTVGYSISLG 197

R15 SLTVAVLILA YFRRRLHCTRN YIHMMFLSP MLRAASIFVK DAVLYSGFTL 250
OkO SLTVAVLILG YFRRRLHCTRN YIHMHLFVSP MLRAVSIFIK DAVLYSGVST 247
Okh SLTVAVLILG YFRRRLHCTRN YIHMHLFVSP MLRAVSIFIK DAVLYSGVST 247
----- C ----- D -----

R15 DEAEERLTEE LHIIAQVPPF PAAAAGVYAG CRVAVTFPLY FLATNYWIL 300
OkO DEIERITEEE LRAFTE...P PPADKAGFVG CRVAVTVPLY FLTTNYWIL 294
Okh DEIERITEEE LRAFTE...P PPADKAGFVG CRVAVTVPLY FLTTNYWIL 294
----- E -----

R15 VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFAVWV GVRATLANTG 350
OkO VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFAVWV TVRATLANTE 344
Okh VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFAVWV TVRATLANTE 344
----- F ----- G -----

R15 CWDLSSGHKK WIIQVPILAS VVLNFILFIN IIRVLATKL ETRAGRC DTR 400
OkO CWDLSSGNKK WIIQVPILAA IVVNFILFIN IIRVLATKL ETRAGRC DTR 394
Okh CWDLSSGNKK WIIQVPILAA IVVNFILFIN IIRVLATKL ETRAGRC DTR 394
----- H -----

R15 QQYRKLLRST LVLVPLFGVH YTVFMALPYT EVSGTLWQIQ MHEYMLFNSP 450
OkO QQYRKLLXST LVLMLPLFGVH YIVFMATPYT EVSGILWQVQ MHEYMLFNSP 444
Okh QQYRKLLKST LVLMLPLFGVH YIVFMATPYT EVSGILWQVQ MHEYMLFNSP 444
----- I -----

R15 QGFFVAIIYC FCNGEVQAEI KKSWSRWTLA LDFKRRKARS SSSYSYGPHV 500
OkO QGFFVAIIYC FCNGEVQAEI KKSWSRWTLA LDFKRRKARS SSTYSYGPHV 494
Okh QGFFVAIIYC FCNGEVQAEI KKSWSRWTLA LDFKRRKARS SSTYSYGPHV 494
----- J -----

R15 SHTSVTNVGP RAGLSLPLSP RLPP...ATT NGHSQLPCHA KPGAPATETE 547
OkO SHTSVTNVGP RGGLALSLSL RLAPGAGASA NGHBQLPGYV KHGSISENSL 544
Okh SHTSVTNVGP RGG..... .NCPESA LD 515

R15 TLPVTMAVFK DDGFLNGSCS GLDEEASGSA RPPFLLOEGW ETVH 591
OkO PSSGPEPGTK DDGYLNG..S GLYEPHVG.E QPPFLLEER ETVH 585

```

12/30

FIG. 6

With 1 enzymes: SACT

February 27, 1992 18:30

GGGATCCCGCGGCCCTAGGCGGTGGCGatgggGAccGCcggatcgacccggcctggcg  
2 ----- 61  
CCCTAGGGCGCGCGGATCCGCCACCGCtaccCTggCGggcctagcgtgggceggaccgc

b M G T A R I A P G L A -

ctccctgctctgctgccccgtgctcagctcccggtacgcgctgggtggatgcagatgacgtc  
62 ----- 121  
gaggacgagacgacggggcacgagtcgaggcgcatgcgcgaccacctacgtctactgcag

b L L L C C P V L S S A Y A L V D A D D V -

atgactaaagaggaacagatcttccctgctgcacggctgctcaggcccagtcgaaaaacgg  
122 ----- 181  
tactgattttctctctgctagaaggacgacgtggcagcagtcgggtcagctcttttgc

b M T K E E Q I F L L H R A Q A Q C E K R -

ctcaaggaggtccctgcagaggccagccagcatatggaatcagacaagggtatggacatct  
182 ----- 241  
gagttctctccaggacgtctccgggtcggctcgtattaccttagtctgttccctacctgtaga

b L K E V L Q R P A S I M E S D K G W T S -

gcgtccacatcaggggaagcccaggaaagataagccatctgggaagctctaccctgagttc  
242 ----- 301  
ggcaggtgtagtcccttcgggtcccttctattccctagacccttcgagatgggactcaga

b A S T S G K P R K D K A S G K L Y P E S -

gaggaggacaaggaggcaccactggcagcaggtaccgagggcgccctgtctgcccggaa  
302 ----- 361  
ctccctccctgttccctccgtgggtgacccgtcgtcccttcgtcccggggacagacggcctt

b E E D K E A F T G S I R G R P C L P E -

tgggaccacatccctgtgctggccgctggggcccccaggtgaggtggtggctgtgccctgt  
362 ----- 421  
accctgggtgtaggacacgacccggcgaccccccgtgggtccactccaccaccgacacgggaca

b W D H I L C W F L G A F E E V V A V P C -

ccggactacatttatgacttcaatcacaaggccctgcctaccgacgctgtgaccgcaat  
422 ----- 481  
ggcctgatgtaaatactgaagttagtggttccgggtacggatggctgcgacactggcggtta

b F D Y I Y D F N H K G A A Y R R C D R N -

ggcacctcggagctcgtgacctgggcaacaacaggacctgggccaactacagcgagtgtgtc  
482 ----- 541  
ccgtccaccctcgaccacggacccctgttctccctcccccgggttgatgtcgtcacacag

13/80

U G S W E L V P S R N R T W A N I F B C V -  
542 aaattttctctcctctgagactcgtggaacgggaggtgtttgaccgcttgggcatcatttac 601  
ttttaaagagtgggttactctgagcacttgcctccacaaactggcggaccggtactaaatg  
b K F L T N E T R E R E V F D R L G M I Y -  
602 accgtgggctactccgtgtccctggcgtccctcaccgtagctgtgctcatcctggcctac 661  
tggcaccgatgagggcacagggaccgcaggagtggtcatcgacacgagtaggaccggatg  
c T V G Y S V S L A S L T V A V L I L A Y -  
662 ttttaggcggctgcactgcacgcgcaactacatccacatgcacctgttctgtccttcctg 721  
aaatccgcgcgacgtgacgtgcgcgttgatgttaggtgtacgtggacaaggacaggaagtac  
b F R R L H C T R N Y I H M H L F L S F M -  
722 ctgcgcgccttgagcatcttctgcaaggacgctgtgctctactctggcgccacgcttgat 781  
gacgcgcggcactcgtagaagcagttcctggacacgagatgagaccgcggtgcgaacta  
b L R A V S I F V K D A V L Y S G A T L D -  
782 gaggtgagcctcaccgaggaggagctgcgcgccatcgcccaggcgccccgcgcct 841  
ctccgaactcgcgagtggtcctcctcgacgcgcggttagcgggtccgcggggcgccgga  
b E A E R L T E E E L R A I A Q A P P P P -  
842 gccaccgcccctgccggctacgcgggtgcagggtggtgtgacctcttctcttacttc 901  
cggtggcgccgacggccgatgcgcctcgactcccaccgacactggaagaaggaaatgaag  
b A T A A A G Y A G C R V A V T F F L Y F -  
902 ctggccaccaactactactggattctgggtggagggtgtacctgcacagcctcatcttc 961  
gaccggtggttgatgatgacctaaagaccacctcccgacatggacctgtcgagtagaag  
c L A T N Y Y W I L V E E L Y L E E L I F -  
962 atggccttcttctcagagaagaagtacctgtggggcttcacagtcttctgggtggggtctg 1021  
taccggaaagaagaagtcttctctctatggacaccccgaaagtgtcagaagccgaccccgac  
o M A F F S E K K Y L N S F T V F G W G L -  
1022 ccgctgtcttctggctgtgtgggtcagtcctcagagctacctggccaacaccgggtgc 1081  
ggcgacagaaagcaccgacacacccagtacagctctcgatgggaccgggtgtggccacg  
b P A V F V A V W V S V R A T L A N T G C -

S  
a  
c  
-

14/30

1032 tgggacttgagctcggggaacaaaaagtggtatcatccagggtgcccctccctgggctccatt  
-----  
acccctgaactcagagggcccttggtttttcacctagtaggtccacgggtaggaccggaggtaa 1141  
b W D L S E S N K K W I I Q V P I L A S I -  
1142 gtgctcaacttcacccctcttcatcaatatcctcgggggtgctcgccaccaagcagcgggag  
-----  
cacgagttgaagtaggagaagtagttatagcaggccacgagcgggtggttcgtcgccctc 1201  
b V L N F I L F I N I V R V L A T K Q R E -  
1202 accaacgcggggccgggtgtgacacacggcagcagcaccggaagctgctcaaattccacgctg  
-----  
tgggtcgggggccgacactgtgtgcccgtcgtccatgggcttcgacgagtttaggtgcgac 1261  
b T N A G R C D T R C C Y R K L L K S T L -  
1262 gtgctcatgcccctcttttggcgtccactacattgctttcatggccacaccatacacccgag  
-----  
cacgagtagcggggagaaaaccgcaggtgatgtacagaaagtaccgggtggtgtatgtggctc 1321  
b V L M P L F G V H Y I V F M A T P Y T E -  
1322 gtctcagggagcgtcttggcaagtcagatccactatgagatgctcttcaactccttccag  
-----  
cagagtcctctgcgagaccgttcaggtctacgtctactctacgagaagttagggaaggtc 1381  
b V S G T L W Q V Q M H Y E M L F N S F Q -  
1382 ggattttttgtcgcaatcatatactgtttctccatggcgaggtacaagctgagatcaag  
-----  
cctaaaaaacagcgttagtatatgacaaaagacgttaccggtccatgttcgactctagttc 1441  
b G F F V A I I Y C F C H S E V Q A E I K -  
1442 aaatcttggagcgggttggacactggcactggacttcagccaaaaggcacgcagcgggagc  
-----  
tttaqaacctcgggcgacctgtgacctgtaccttacttccgttcggtcgccctcg 1501  
b K S W S R W T L A L C F H R K A R S G S -  
1502 agcagctatagctacggcccccattggtgtcccccacaaagtgtgaccaatgtcggtccccgt  
-----  
tcgtcgatatcgatccgggggtaccacaggggtgtgtccactggttacagcggggggca 1561  
b S S Y S Y G P M V S R T E V T N V G P R -  
1562 gtgggactcggccctgcccctcagccccccctactgcccactgccaccaccaacggccac  
-----  
caccctgagcgggacggggagtcgggggggggttcccggtgacggtggtggttgcgggtg 1621  
b V G L G L P L S P R L L P T A T T N G H -  
1622 cctcagctgctcggccatgccaaagccagggacccccccctggagacctcgagaccaca  
-----  
ggagtcgacggacgggtacggttcgggtccctgggttcgggacctctgggagctctggtgt 1681  
b F Q L P G H A K P G T T A L E T L E T T -

15/30

1682 ----- 1741  
gggggacgggtaccgacgggggttcctgctacccaaaggagctgcccaggacgagtcgggac

b P P A M A A P K D D G F L N G S C S G L -

1742 ----- 1801  
ctgctcctccggagacccggactcgccggcggacgggacgagtccttctcaccctctgt

b D E E A S G P E R P P A L L Q E E W E T -

1802 ----- 1861  
cagtacactgggtccgacccccgacctggacgactgtatcacctacctgtctacctggt

b V M

1862 ----- 1921  
tttttaccacccaacttactaaagggtgagtcggggaccccggttctctcttttttctccc

b

1922 ----- 1981  
cttttttctttttttttcttttttcccttttttttttttttttttttttttttttttt

b

1982 ----- 2011  
tttttttttttttttttttttttttttttt

b

Enzymes that do cut:

SacI

16/30




Fig. 7


17/30

Fig.3

PERIOD of: 1K.Pep ck: 7509, 1 to 594 March 7, 1992 16:26  
 TRANSFER of: 1K.seq ck: 9/54 from: 29 to: 1810




FIG. 9




19/30

FIG. 10




20/30

Fig. 11



21/30

FIG. 12








FIG. 13

FIG. 14



24/30

FIG. 15



25/30

FIG. 16




Fig. 17







Fig. 18




Fig. 19





Fig. 20




(3)

## RAT BONE PTH/PTHrP RECEPTOR



## AMINO ACID SEQUENCE OF 7 PUTATIVE TRANS-MEMBRANE REGIONS



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/02821

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 435/69.1, 240.2, 320.1; 536/27, 28, 29; 530/350, 387, 397, 399.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : APS AND COMMERCIAL DATABASES (DIALOG) 435/69.1, 240.2, 320.1; 536/27, 28, 29

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG AND ONLINE SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	TWENTY-SEVENTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, VOLUME 105, NO. 4, PT. 2, ISSUED OCTOBER 1987, R. A. LUBEN ET AL., "MOLECULAR CLONING OF A PARATHYROID HORMONE RECEPTOR-RELATED MEMBRANE PROTEIN FROM MOUSE BONE CELLS", ENTIRE DOCUMENT.	<u>1-19, 39</u> 20-38, 40-49
Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL 265, NO. 1, ISSUED 05 JANUARY 1990, ABOU-SAMRA ET AL., "CHARACTERIZATION OF FULLY ACTIVE BIOTINYLATED PARATHYROID HORMONE ANALOGS", PAGES 58-62, ENTIRE DOCUMENT.	1-49
Y	BIOCHEMISTRY, VOLUME 29, NO. 30, ISSUED 31 JULY 1990, JUPPNER ET AL., "PREPARATION AND CHARACTERIZATION (N-(4-AZIDO-2-NITROPHENYL)ALA, TYR-36)-PATHYROID HORMONE RELATED PEPTIDE (1-36) AMIDE: A HIGH-AFFINITY, PARTIAL AGONIST HAVING HIGH CROSS-LINKING EFFICIENCY WITH ITS RECEPTOR ON ROS 17/2.8 CELLS", PAGES 6941-6946, ENTIRE DOCUMENT.	1-49

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be part of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to underpin the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\*

document member of the same patent family

Date of the actual completion of the international search

01 JULY 1992

Date of mailing of the international search report

31 JUL 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No.

Authorized officer

GIAN WANG

Telephone No. (703) 308-3993

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/02821

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C12P 21/06; C12N 5/00, 15/00; C07H 15/12, 17/00; C07K 3/00; A61K 35/14, 37/24, 37/36.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING